On the Concept for the Development of the National Center for Biotechnology of the Republic of Kazakhstan for 2006–2008
Resolution of the Government of the Republic of Kazakhstan dated May 3, 2006 No. 363.
For the purpose of developing science in the field of biotechnology in the Republic of Kazakhstan, the Government of the Republic of Kazakhstan HEREBY RESOLVES:
1. To approve the attached Concept for the Development of the National Center for Biotechnology of the Republic of Kazakhstan for 2006–2008.
2. To approve the attached Action Plan for the Implementation of the Concept for the Development of the National Center for Biotechnology of the Republic of Kazakhstan for 2006–2008.
3. This Resolution shall enter into force on the date of its signing.
| Prime Minister of the Republic of Kazakhstan | || ----------------------------------- | - |
| | Approved by Resolution of the Government of the Republic of Kazakhstan dated May 3, 2006 No. 363 || - | -------------------------------------------------------------------------------- |
CONCEPT FOR THE DEVELOPMENT OF THE NATIONAL CENTER FOR BIOTECHNOLOGY OF THE REPUBLIC OF KAZAKHSTAN FOR 2006–2008
Astana – 2006
CONTENTS
1. Analysis of the Current State of Biotechnology
§ 1. Analysis of the State of the Global Biotechnology Products Market and Development Trends
§ 2. Main Areas of Biotechnology
§ 3. Main Prerequisites for the Development of Biotechnology in Kazakhstan
§ 3.1. Assessment of Existing Demand and Supply for Biotechnological Products in Kazakhstan
§ 3.2. Relevance of Biotechnology Development in Kazakhstan
3. State Policy in the Field of Biotechnology as the Main Mechanism for Implementing the Concept
§ 3. Issues of Intellectual Property Rights Protection
§ 4. Development of the Regulatory Legal Framework
5. Stages and Expected Results of the Implementation of the Concept
§ 1. Stages of Implementation of the Concept
§ 2. Expected Results of the Implementation of the Concept
6. Required Funding Amounts and Sources
Introduction
In highly developed countries, a four-level sectoral division of the economy has emerged, namely:
industries engaged in the extraction and primary processing of raw materials;
traditional industries;
high-tech industries, characterized by relatively low material and labor intensity, but a very high share of expenditure on research and development (hereinafter referred to as R&D) in value added;
the sector of “soft” technologies (services), such as software development, systems integration, consulting, and education.
In traditional sectors of the economy, the main part of value added is created either in the process of extracting and initially processing raw materials or in the process of manufacturing products (the second group of industries).
The innovation process constitutes the main substance of the process of modernizing the economy and society as a whole and is based, above all, on the extensive use of the results of intellectual labor.
The modern approach to analyzing the structure of “value accumulation chains” indicates that the stages of the innovation cycle associated with “intangible” components make the greatest contribution to future profits. The main elements of this part of value added are created in the process of R&D, the use of intellectual property rights, and effective management.
At present, there is a clearly discernible trend towards the transformation of the national economies of the world's leading countries from traditionally industrial economies into post-industrial economies, that is, economies based on knowledge and high technologies.
The Strategy for Industrial and Innovative Development of the Republic of Kazakhstan for 2003–2015 clearly defines Kazakhstan's commitment to the industrial and innovative path of economic development.
The arguments presented indicate the need to change the sectoral structure of Kazakhstan's economy towards a significant increase in the share of high-tech, knowledge-intensive industries. However, under the conditions prevailing in our country, the continuing high rates of economic growth must not lead to a loss of vigilance or a sense of complacency. It should be remembered that this is the initial effect of the systemic reforms carried out in the Republic, as well as of the favorable market conditions for oil on the world market. The raw-material orientation of the economy will not allow the Republic to enter a zone of stable growth. Industrialization is necessary to create a stable economy, while the introduction of a knowledge-intensive innovative component together with a high-technology industry is necessary to achieve sustainable growth and create an efficient economy. Under the conditions prevailing in Kazakhstan, the following areas may serve as such growth points:
information technology;
aerospace;
biotechnology;
nuclear technology.
This is обусловлено by the inherited infrastructure and human resource potential in these areas.
The Concept for the Development of the National Center for Biotechnology of the Republic of Kazakhstan for 2006–2008 (hereinafter referred to as the Concept) is devoted to the development of biotechnology in Kazakhstan on the basis of the development of the “National Center for Biotechnology of the Republic of Kazakhstan” (hereinafter referred to as the NCB).
1. Analysis of the Current State of Biotechnology
Biotechnology is one of the important areas of scientific and technological progress. Based on modern achievements in biological and technical sciences, genetic and cell engineering, it is possible to use the potential capabilities of purposefully created living systems (primarily microorganisms) to improve people's standard of living. Biotechnological products make it possible to address production and technological, environmental, and socio-economic problems, both in the near future and from a strategic perspective.
For every country, including Kazakhstan, issues concerning future development are important, whether they relate to the health of the nation, economic well-being, or defense capability. Biotechnology plays an important role in addressing these issues, as it accumulates the achievements of the most knowledge-intensive industries, thereby stimulating their development and extending the results achieved to all other sectors, allowing them to advance dynamically to an entirely new qualitative level.
Today, when the opportunities for economic growth through the involvement of new resources in economic circulation are severely limited, forecasts clearly assign biotechnology one of the key roles in the economic development of human society.
According to the conclusions of experts from the United Nations, in the 21st century biotechnology will determine the development of humanity in all spheres of its activity and, first and foremost, in the production of food products and medical preparations, in agriculture, ecology, and energy.
The changes that have taken place in biology over recent decades have opened up fundamentally new prospects for the development of biotechnology, expanded the scope for applying biological processes in production, and led to the emergence of new areas united under the general name of “modern biotechnology”.
§ 1. Analysis of the State of the Global Biotechnology Products Market and Development Trends
The development of modern biotechnology methods has led to the formation of an independent commodity market for biotechnological products. Biotechnology is one of the areas of development of industry and agriculture that has macroeconomic significance. Therefore, given its enormous importance in terms of economic efficiency, national and international biotechnology programs financed by public and private capital have been developed and are operating in all leading countries of the world.
Thus, the annual growth rate of the global biotechnology industry market is approximately 7%.
In particular, the annual sales volume of biotechnological preparations worldwide amounted to:
food industry and agriculture – USD 46 billion;
seed material of genetically modified plants – USD 30 billion;
pharmaceutical preparations – USD 27 billion;
enzymes for the production of detergents – USD 21 billion;
therapeutic and cosmetic products obtained from plant and animal raw materials – approximately USD 40 billion.
By 2010, the total biotechnology market volume was forecast to exceed USD 2 trillion.
More than half of the turnover of the modern global bioindustry is accounted for by the United States. By comparison, the volume of biotechnology funding in the United States amounts to USD 100 billion, in China – USD 1 billion, and in Russia – USD 0.04 billion annually, whereas in Kazakhstan, for 2005, approximately USD 1 million (USD 0.001 billion) was allocated in the national budget for targeted research and development in the field of biotechnology.
Japan ranks second in the world after the United States in terms of the level of biotechnology development. Having strong positions in traditional areas of this industry, particularly in the production of enzymes, antibiotics, and amino acids, it lags significantly behind the United States in the application of the latest biotechnology methods. At present, only about 5% of Japan's pharmaceutical industry's R&D expenditure is allocated to genetic engineering research, and approximately 120 companies have their own programs for developing methods of obtaining medicinal products using the latest biotechnology methods. Close cooperation between the public and private sectors is of great importance for the development of biotechnology in Japan, and the government of the country participates in the implementation of certain biotechnology programs.
Alongside the United States and Japan, biotechnology is developing rapidly in the countries of Western Europe. By coordinating their activities, these countries may exert a significant influence on the market conditions for biotechnological products in the future. In Western Europe, biotechnology companies emerged mainly on the basis of laboratories that had previously conducted fundamental scientific research. Many of them are currently financed by industrial corporations and financial institutions or receive financial support from the government.
Biotechnology development programs financed by the governments of Western European countries are focused on implementing targeted programs or achieving specific commercial objectives (unlike in the United States, where government efforts are directed mainly towards supporting fundamental research, while private-sector enterprises and organizations develop practically without government financial support).
The International Center for Genetic Engineering and Biotechnology (ICGEB) was established under the auspices of UNESCO and brings together 45 countries from Europe, Asia, Africa, and Latin America. Member countries conduct scientific research and develop biotechnological products in the fields of healthcare, agriculture, industry, and ecology.
The objectives of ICGEB are: promoting international cooperation in the development and peaceful application of genetic engineering and biotechnology; assisting developing countries in strengthening their scientific and technological capacity in the field of genetic engineering and biotechnology; and developing the exchange of information, experience, and know-how among specialists in science and technology from participating countries.
Overall, the biotechnology industry is represented by more than 3,000 biotechnology companies, academic institutions, government biotechnology centers, and other organizations worldwide.
Bioindustry in the United States
The United States may be considered the birthplace of biotechnology.
Between 1980 and 1983, approximately 200 small biotechnology companies were established in America. This was facilitated by the introduction of tax incentives, high profits from securities transactions, and the interest of private investors. Following Herbert Boyer, a researcher at the University of California, San Francisco, who became vice president of the biotechnology company Genentech, many university professors established their own companies.
By 1985, more than 400 biotechnology firms were operating in the United States; many of them included the word “gene” in their names to demonstrate their affiliation with the genetic engineering sector: Biogen, Amgen, Calgene, Engenics, Genex, Cangene. Today, there are more than 1,500 biotechnology companies in the country. In addition, all major international chemical and pharmaceutical companies, including Monsanto, DuPont, Upjohn, American Cyanamid, Eli Lilly, SmithKline Beecham, Merck, Novartis, and Hoffman-LaRoche, have made a significant contribution to the development of molecular biotechnology.
During the period of rapid development of the biotechnology business in the 1980s, small companies were acquired by large ones, and joint ventures were established. For example, in 1991, 60% of Genentech's shares were sold to Hoffmann-La Roche for USD 2.1 billion. At the same time, many companies went bankrupt. Such mobility is a characteristic feature of the biotechnology industry.
The revenue of the molecular biotechnology industry increased from USD 6 million in 1986 to USD 30 billion in 1996 and currently amounts to USD 160 billion annually.
Although the overall profitability of the biotechnology business turned out to be not as high as expected, investors' enthusiasm has not diminished, indicating that molecular biotechnology has great prospects.
All new independent molecular biotechnology companies choose a narrow specialization, which is reflected in their names and indicates to observers that the market is deeply saturated. For example, following companies engaged in gene cloning, companies producing antibodies obtained through genetic engineering methods appeared in the United States. These antibodies are intended for the treatment of infectious diseases, cancer, and other human diseases: Immunex, ImmuLogic, ImmunoGen, Immunomedics, Medlmmune, Immune Response.
At present, innovative structures such as biotechnology clusters are becoming increasingly important. One of the most developed clusters in the United States is located in the state of Massachusetts. It includes several dozen biotechnology firms producing a wide variety of products, ranging from medicinal preparations to genetically modified plants. Laboratory research for the cluster is conducted at renowned research centers, including the Massachusetts Institute of Technology, Harvard University, and Boston University. Clinical trials are carried out by hospitals in the Boston area.
Biotechnology Industry in Europe
The European biotechnology industry is also developing steadily. By 1995, more than 600 biotechnology companies had been established in European countries. In countries other than the United States that entered the biotechnology era at a later stage, the state assumed the leading role in the development of the national molecular biotechnology industry. The driving force was the belief that molecular biotechnology was “the most revolutionary of all technologies of the 20th century”.
A sufficiently favorable market environment for the industry has developed in Europe. In the field of biotechnology, European countries have lower wage levels than the United States, where employees cost 30% more. In Europe, there are no difficulties in recruiting qualified personnel due to the high level of development of education. The main difference is that in Europe many things are prescribed by law, whereas in America they are determined by the market.
Bioindustry in Japan and China
In view of the above, the majority of commercial developments in the field of molecular biotechnology are concentrated in the United States. In other countries, where the investment climate is less favorable and business activity is lower, large corporations and the state play the main role in establishing molecular biotechnology enterprises. For example, the Government of Japan declared biotechnology a “strategic industry” and a national priority. Large Japanese corporations took up the task. Initially, they lacked their own personnel, and the first research projects were conducted in cooperation with American universities and companies. At present, these corporations have acquired the necessary experience and independently conduct molecular biotechnology developments and create genetically engineered products.
In accordance with the updated program for the development of high-tech industries through 2010, adopted by the Government of Japan in 2002, the practical application of biotechnology was recognized as one of the key areas. Companies specializing in this field are actively promoting their products in domestic and foreign markets. This is facilitated by such factors as:
the availability of the necessary technical equipment for conducting R&D;
support from the state authorities of Japan.
Biotechnology is developing at a high rate in China. Chinese research institutes have developed 141 types of genetically modified plants, 65 of which have already been approved for cultivation.
More types of plant products are being developed through biotechnology in China than in any other country outside North America. China's achievements in this field refute the existing notion that developing countries, which are primarily interested in obtaining biotechnological products, will not be able to make use of Western technologies.
The creation of genetically modified plants in China is financed entirely by the state. The authorities' interest in developing the production of transgenic food products is quite understandable, since traditional agriculture apparently will not be able to feed the rapidly growing population of the world's most populous nation.
Bioindustry in Russia
The development of the Russian biotechnology industry began with the establishment of the Main Directorate of the Microbiological Industry under the Council of Ministers of the USSR. For the first time, an industry based on microbial synthesis was organized, producing the widest range of products from various types of readily available and sufficiently inexpensive raw materials. At present, the biotechnology industry comprises more than forty enterprises and organizations.
The deep economic crisis of the 1990s did not spare the Russian biotechnology industry. While the USSR produced 3–5% of the world's biotechnology industry output and ranked second in the world in the development of the microbiological industry, уступая лишь США, the Russian Federation currently produces less than 1% of the global output of such products. At the same time, the production of a number of key products, including antibiotics and vitamins, has practically ceased; enzyme production has fallen sixfold, antibiotic production twelvefold, and feed protein production twenty-fivefold. Russia accounts for 0.02% of the global production of genetically engineered medicines for medical use. Russia's dependence on imports of the most important types of biotechnological products is exceptionally high: for example, it amounts to almost 100% for insulin and more than 90% for antibiotics.
The volume of the biotechnology market in Russia reached USD 510.6 million in 2003. This figure looks quite modest compared, for example, with the volume of the Russian IT market, estimated at approximately USD 2.5 billion.
Although this industrial sector in Russia has not disappeared completely, domestic policy over the past decade and a half has led to significant imbalances in its development. For example, the production of ethyl alcohol accounts for 70% of the industry's total production volume.
§ 2. Main Areas of Biotechnology
Over the next 10 years, a significant expansion in the areas of application of biotechnology is forecast in such important sectors of the economy as fine chemicals (biocatalysts, organic synthesis products), extractive industries (biogeotechnology, soil bioremediation), semiconductor production (new materials), and information technology (microelectronic systems, bioinformatics tools, devices based on biological principles, biocomputers). In certain industries, the introduction of biotechnological methods will lead to qualitative changes in the production base.
Products obtained using biotechnology will account for approximately 30% of the global chemicals market by 2010. The volume of this market is estimated at USD 1.5 trillion. The widespread adoption of genetically modified crops will lead to an annual 30% reduction in sales of herbicides and pesticides.
Genetic engineering has become widely developed in global biotechnology. The main focus of all global research in the field of bioengineering is the creation of genetically modified organisms (GMOs) with specific traits beneficial to humans. In a broad sense, there are three main objectives of genetic engineering activities: the creation of genetically modified (hereinafter referred to as GM) plants, GM animals, and GM microorganisms for the pharmaceutical and food industries.
Medicinal products obtained through genetic engineering (in particular, synthetic insulin, recombinant interferon, and vaccines against hepatitis B) enjoy a good reputation in scientific circles worldwide and stable demand among consumers. Genetically engineered medicinal products, primarily those based on human and animal proteins, in most cases can only be obtained through biotechnology and are becoming indispensable in the treatment of serious diseases. For example, the use of prourokinase, a fourth-generation thrombolytic agent, reduces mortality from myocardial infarction fivefold. The use of lactoferrin reduces the incidence of gastroenteritis among artificially fed infants tenfold.
Genetically Engineered Pharmaceutical Substances
At present, the production of 143 genetically engineered pharmaceutical substances has been authorized worldwide, while 26 are at the stage of obtaining authorization. Decoding the human genome makes it possible to assume that new human regulatory proteins will be discovered in the near future and that new-generation medicinal products will be developed on their basis, with production expected to begin in two to three years. According to expert forecasts, in 10 years they will account for 15 percent of the global pharmaceutical industry, and in 20 years they will replace at least half of all currently existing medicinal products.
Scientists first applied genetic engineering methods to microorganisms. One of the first genetically modified products was insulin: a gene responsible for its synthesis was inserted into the deoxyribonucleic acid (hereinafter referred to as DNA) of a bacterium. Today, practically all insulin worldwide is produced industrially using transgenic bacteria.
A little later, scientists discovered that many essential proteins could not be obtained using bacteria and began developing transgenic plants and animals possessing beneficial properties. Pharmaceutical products can be manufactured not only using transgenic animals but also plants.
Another area of scientific research is the development of animals and plants that possess increased resistance to diseases or other beneficial properties. According to experts, this is a highly promising and profitable area of scientific and industrial development. According to expert estimates, in 2010, global revenue from the application of genetic engineering technologies would exceed USD 1 trillion.
The situation is quite different in the field of genetically modified plants, which are actively spreading throughout the world and encountering equally active resistance in a number of countries. The main question actively discussed in connection with genetically modified plants is how safe they are for humans and the environment.
Biotechnology in Bioengineering
Biotechnology based on genetic engineering includes the following areas:
protein and cell engineering;
engineering enzymology;
biosensor technology;
immunodiagnostics based on monoclonal and polyclonal antibodies.
The main purpose of biotechnology based on bioengineering is to improve living organisms and obtain new biologically active compounds with enhanced characteristics that have no analogues in nature.
Biotechnologies based on bioengineering are applied in the following fields:
healthcare and pharmaceuticals (development of a new generation of diagnostic products and medicinal products based on recombinant proteins, enzymes and hormones);
various industrial sectors (development of biocatalysts, recombinant enzymes and modified microorganisms to intensify industrial processes);
agriculture (development of transgenic plants and animals with improved properties and increased productivity, use of genetically engineered growth regulators and biofertilizers);
environmental protection (waste disposal, biodegradation of xenobiotics, water purification).
Genetically altered or genetically modified products are products obtained from plants into whose DNA a specific gene, not naturally present in them, has been introduced, as a result of which they acquire various new properties.
Three stages in the development of new plant forms are distinguished:
the first stage – the development of plants with some new property, such as resistance to viruses, parasites or herbicides. The relatively rapid success in developing plant varieties at the first stage was largely explained by the fact that the introduced resistance trait was determined by a single gene, and the sources of genes were either plant viruses or soil bacteria (genes conferring resistance to insects and herbicides). In other words, well-studied, simple biological objects naturally present in the environment were used as gene donors;
at present, Kazakhstan is possibly two to three years away from reaching the peak of the second stage – the development of plants with new agronomic functional properties. First and foremost, this includes altered oil composition in oilseed crops, as well as fruits and vegetables with increased vitamin content and cereal crops with grains of higher nutritional value;
today, plants of the third stage are being developed in the world's leading laboratories, and their appearance on the market can be expected within the next ten years. Several fundamental areas are involved: plant vaccines, plants functioning as factories for the production of industrial products such as various types of plastics, dyes (for example, indigo), technical oils and engine additives. In fact, this could involve the creation of a new, significantly cleaner industry for the production of essential technological products.
Biotechnology in Medicine
The global market for pharmaceutical products manufactured using biotechnological methods accounts for approximately half of the biotechnology market.
Antibiotics
The average annual growth rate of the global antibiotics market in the 1980s was 10–15%, while in 1991–1998 it stood at 11–12%, exceeding 20% for certain groups of antibiotics. Sales of the quinolone ciprofloxacin (BAYER), clarithromycin (USA) and cephalosporin (HOFFMANN – La ROCHE) exceeded USD 1 billion. Today, a significant portion of fermentation capacity for the production of antibiotic substances remains idle. Kazakhstan mainly purchases antibiotic substances and finished dosage forms.
Immunological Preparations
These include therapeutic, diagnostic and preventive products comprising vaccines, therapeutic sera, toxoids, immunoglobulins, bacteriophages, interferons, normal flora preparations, allergens and others. For example, approximately 300 types of products are currently purchased in Russia, while around 500 types of immunobiological products are manufactured there. Throughout the world, only integrated systems combining a research laboratory with a powerful production base manufacture high-quality products that are competitive on foreign markets. The practical absence of a fully developed market for immunobiological products in the country and the lack of domestic production mean that the Republic not only has no access to global markets but may, on the contrary, remain a potential importer for many years.
Biotechnological Blood Products
At present, in developed countries, the production of medical preparations from donor blood plasma is regulated by strict control standards that exclude contamination of products not only with hepatitis B and C antigens, AIDS and sexually transmitted infections, but also with cytomegalovirus and T-cell leukemia. However, the production of blood products is currently not considered sufficiently modern, since even high-quality blood products may contain non-enveloped viruses (hepatitis A, parvovirus B19 and others). Recombinant blood factor concentrates are significantly safer, as there has not been a single documented case of viral transmission associated with them. The production of purified blood factors, both recombinant and plasma-derived, is currently absent. The economic situation does not allow the principles of standardization to be implemented sufficiently in the production of blood products, which may consequently become infected.
Genetically Engineered Medicinal Products
These are natural bioregulators and biologically active substances whose synthesis for medical purposes outside the body is impossible or extremely difficult. At present, the production of genetically engineered medicinal products is the leading sector of the biotechnological pharmaceutical industry. The largest production sector is the production of genetically engineered insulin, whose share of the global market for products of the latest biotechnological industry amounted to 18%, representing more than USD 3 billion in monetary terms. In recent years, the sales leaders in the market for genetically engineered hormonal medicines have been recombinant erythropoietin preparations, various modifications of which are used in the treatment of anemia, cardiovascular diseases and oncological diseases. Monoclonal antibodies (MABs) occupy a leading position among biotechnological products under development and have found application in immunodiagnostics, cancer therapy and the treatment of other diseases. Among the most actively developed genetically engineered products are preparations belonging to the cytokine group – interleukins, as well as interleukin receptor antagonists. These preparations are promising for the treatment of tumors, inflammatory and autoimmune diseases, as well as severe forms of blood diseases.
Diagnostic Products
Traditional diagnostic methods based on bacteriological and physicochemical analyses are actively being replaced by immunological and DNA diagnostics. Research into the development of products and equipment for conducting rapid tests and detecting diseases at early stages, including sexually transmitted diseases, hepatitis, HIV, tuberculosis and cancer, is developing rapidly. Rapid analyzers are undergoing testing that, throughout their entire service life (18 months), are capable of reliably indicating the presence of HIV antibodies in a person's body through saliva analysis. The result of this very simple test is ready in just 20 minutes, and its accuracy is 99.6%.
Biosensors and Biochips
The term "biosensor" should be understood as a device in which a sensitive layer containing biological material – enzymes, tissues, bacteria, yeasts, antigens/antibodies, liposomes, organelles, receptors, DNA – directly responds to the presence of the component being detected and generates a signal functionally related to the concentration of that component. Structurally, a biosensor is a combined device consisting of two converters, or transducers – a biochemical and a physical one – located in close contact with each other.
The market volume amounts to approximately USD 70 billion, with biosensors accounting for more than 20% and their share constantly increasing. Several types of biosensors currently exist. These include enzyme electrodes, enzymatic microcalorimetric sensors and biosensors based on chemiluminescence and bioluminescence.
Biological microchips are miniature devices designed to conduct various biochemical analyses. These are microplates with densely arranged spots of reactive agents applied to them, capable of interacting with certain substances contained in the analyzed samples. They are tools for studying the fine mechanisms of mutual regulation between genes and their products, which is one of the fundamental tasks of molecular biology. DNA microchips on nylon membranes – filters containing genes of microorganisms, plants, mammals and humans – are currently available, together with software from various companies. The development of protein microchips presents a more complex challenge. The creation of protein microchips attracts substantial investment. A new scientific field – proteomics – is devoted to the study of proteins, their synthesis in living organisms, their interactions and their very complex relationships. Scientists at the Institute of Molecular Technology have developed biochips – test systems that make it possible to identify a wide variety of substances quickly and with the highest possible accuracy. A biochip is a small glass plate onto which dozens of barely visible hemispherical hydrogel cells, each less than 100 microns in diameter, are applied. Biologically active macromolecules in a functionally active state are chemically attached inside them and are capable of selectively binding molecules of substances contained in the analyzed solutions. In the early stages of certain diseases, minor changes occur in a number of proteins. Russian and French scientists are developing equipment capable of detecting and analyzing these changes.
In recent years, with the development of DNA chip technology, so-called DNA sensors, which use physical methods to detect the processes of selective sorption of certain molecules on solid surfaces, have begun to be widely applied.
A DNA sensor has high sensitivity, small dimensions, implements a contactless measurement method in a small volume, has a simple design and can be inexpensive to manufacture.
Biotechnology of Active Substances and Products of Plant Origin
Biologically active substances of plant origin represent a broad range of infinitely diverse materials whose chemical synthesis is often practically impossible.
The major consumers of products of plant origin remain the food industry and beverage production, and their demand in 2003 amounted to USD 560 million. For example, medical and perfumery preparations based on the biomass of ginseng and Rhodiola rosea cells are currently being manufactured in Russia.
The production of biologically active and medicinal preparations using plant cell cultures is already widespread and offers considerable prospects.
Market Demand for Products of Plant Origin
Table 1
| Product Name | 1993 | 1999 | 2003 | 2008* | Average Annual Growth, % (1993–2003) |
|---|---|---|---|---|---|
| Total market demand for products of plant origin (USD million), including: | 1185 | 1890 | 2935 | 4495 | 9.9 |
| Essential oils | 155 | 625 | 820 | 1054 | 6.1 |
| Botanical extracts | 268 | 560 | 1120 | 1990 | 15.9 |
| Resins, gels and polymers | 274 | 392 | 500 | 660 | 7.4 |
| Enzymes and oxyacids (α and β) | 170 | 300 | 480 | 790 | 11 |
| Production of products of plant origin, tonnes | 170000 | 240000 | 340000 | 450000 | 7.7 |
\* – Expert forecast
Note of the RCI: α – Greek alpha, β – Greek beta.
Biotechnology of Biologically Active Supplements (BAS)
Different countries classify these products in different ways. In Kazakhstan, they consist of 3 groups:
parapharmaceuticals – substances similar to medicines;
nutraceuticals – food products enriched with health-promoting supplements;
vitamin and mineral complexes.
All the above-mentioned groups of BAS are obtained from raw materials of plant and animal origin through both chemical extraction and biotechnological methods. Bringing BAS to the market does not require authorization procedures similar to those required for the release of medicinal and diagnostic products, which has made their production attractive and led to the participation of practically all the world's largest pharmaceutical and biological companies in this field.
The data accumulated to date from studies of the dietary structure of modern humans indicate the widespread occurrence of insufficient consumption of essential food components.
Optimizing the diet of modern humans in accordance with recommended consumption standards cannot be achieved simply by increasing the consumption of natural food products without causing harm to health; it requires new approaches and solutions. One such approach involves biologically active food supplements in the form of multivitamin formulations, vitamin and mineral mixtures, and plant complexes that serve as sources of natural biologically active substances.
This leads to the conclusion that there is a need for a more accessible and faster way of additionally supplying the body with these deficient substances than increasing the volume of food production. This role should be fulfilled by biologically active food supplements, which are widely used throughout the world and consumed with meals either in various pharmaceutical forms (infusions, extracts, balms, syrups, concentrates, isolates, powders, tablets, capsules and so on) or as food products enriched with biologically active substances. The feasibility of this approach to improving nutrition and public health is substantiated by the achievements of bioorganic chemistry and biotechnology (the achievement of complete and high-quality isolation of substances), nutrition science and pharmacology (the elucidation of the mechanisms of action and transformations of biologically active substances in the body).
Biotechnology in Agriculture
The agricultural biotechnology sector consists of veterinary biotechnological products, biotechnological plant protection products, and transgenic plants and animals.
Biotechnological Means of Animal Protection
The antibiotics market in animal husbandry includes:
growth promoters – sales volume amounts to between USD 1.0 billion and USD 1.7 billion;
antibiotics for therapy and prevention – up to USD 2.0 billion;
antiparasitic agents – USD 3.3 billion.
Experts believe that antibiotics used as growth promoters in feed additives will soon be replaced by probiotics, amino acids, vitamins, enzymes and plant extracts. Biotechnology is being used to address the problems of obtaining animals resistant to diseases.
Biotechnology in Animal Husbandry
A major achievement of biotechnology is the development of the embryo transplantation method, the essence of which is that an embryo from a highly productive cow is transferred to an ordinary cow, resulting in a calf that inherits the traits of its high-bred parents. A method for determining and controlling sex at the cellular level has been developed, which offers considerable prospects for optimizing herd structure.
Biologically active feed additives (BAFAs) and mineral-vitamin premixes play an enormous role in intensifying animal husbandry and breeding new breeds.
The most widespread and economically effective method of enriching compound feed with vitamins is introducing them into feed raw materials as part of premixes. A premix is an enrichment complex of biologically active substances produced through chemical and microbiological synthesis.
Biotechnological Means of Plant Protection
Commercial success currently accompanies manufacturers of plant protection products that have switched to producing more effective or less environmentally harmful preparations, including biopesticides – products of microbial, plant and animal origin whose application is environmentally safe. Biopesticides are represented by two groups – microbial and biochemical pesticides. Microbial pesticides contain microorganisms – bacteria, viruses and fungi – as their active ingredient. Biochemical pesticides are substances of natural origin (pheromones, growth regulators, regulators of reproductive functions) that control the growth and spread of pathogens and pests of agricultural plants without exerting a toxic effect on the environment. In order to reduce the cost of biopesticides, technologies are being developed for using dried microorganisms – bacteria and fungi – after they have been cultivated in fermenters under farm conditions.
Biotechnological (Transgenic) Species of Plants and Animals
The fastest-developing area of biotechnology is transgenesis – the creation of transgenic plants and animals through genetic engineering.
Transgenic Plants
In 2002, the total area cultivated with transgenic varieties continued to grow for the sixth consecutive year at a rate of more than 105% per year. In 2002, it amounted to 58.7 million hectares, and approximately 6 million people were engaged in this business. This is almost twice the area of the United Kingdom or more than 50% of all arable land in the Russian Federation, where not a single transgenic crop is yet being commercially cultivated. Between 2001 and 2002, the area planted with genetically modified (GM) plants worldwide increased by 12%, while between 1996 and 2002 it increased 35-fold. Such high rates of adoption have no precedent in comparison with any other technology throughout the history of agriculture. Over the past seven years, the number of countries growing transgenic crops has more than doubled, reaching sixteen.
The predominant transgenic crop in 2002 was soybean, followed by maize in second place, cotton in third place, and winter rapeseed thereafter.
Areas Occupied by Individual Crops and Their Changes in 2002
Table 2
| Crop | Area, million hectares | Share of Total Area of Transgenic Crops, % | Increase, % ||---|---:|---:|---:|| Soybean | 36.5 | 62 | +10 || Maize | 12.4 | 21 | +27 || Cotton | 6.8 | 12 | – || Winter rapeseed | 3 | 5 | +11 || Squash |
Enzymes for the production of detergents, %
| Type of product | 1992 | 1993 | 1994 | 1995 | 1996 | 1997 | 1998 | 2005* | 2009* |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
Enzymes for the production of detergents, %
| 42 | 40 | 41 | 35 | 36 | 34 | 32 | 33 | 29 || -- | -- | -- | -- | -- | -- | -- | -- | -- |
Enzymes for the textile industry, %
| 15 | 13 | 15 | 3 | 10 | 7 | 5 | 4 | 4 || -- | -- | -- | - | -- | - | - | - | - |
Enzymes for the processing of carbohydrate raw materials, %
| 18 | 18 | 14 | 16 | 16 | 16 | 16 | 13 | 15 || -- | -- | -- | -- | -- | -- | -- | -- | -- |
Enzymes for the dairy industry, %
| 19 | 18 | 16 | 18 | 14 | 15 | 14 | 11 | 12 || -- | -- | -- | -- | -- | -- | -- | -- | -- |
| (i) Others, % | 6 | 11 | 14 | 18 | 24 | 28 | 33 | 39 | 40 || ------------- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
* Expert forecast
Over the past 5–6 years, the production of baking enzymes and feed additives has doubled. The market for feed enzyme additives intended to improve the digestibility and nutritional value of animal feed is estimated at USD 105 million. The market for enzymes used in various sectors of food production reaches USD 540 million. Enzymes for wastewater treatment also have considerable potential and a wide range of applications.
In the food industry, the use of enzymes makes it possible to organize low-cost and dynamic production of food products from available and inexpensive types of agricultural raw materials and food industry waste.
90% of industrial enzyme production is concentrated in Europe, Japan and the United States. China and India supply the Asian markets. Overall, the global market for industrial enzymes is estimated at USD 1.5 billion.
Biotechnology in the Extractive Industries
Biotechnologies based on the use of various groups of microorganisms are increasingly being applied in oil production and in the remediation of environmental sites contaminated with oil.
An important area of biotechnological research is the development of new technologies to protect the environment from pollution caused by waste from various industrial processes and to clean up areas that have already been contaminated.
Mining Industry
The advantages of biotechnological methods for extracting and processing gold and other precious and rare-earth metals lie not only in their environmental and economic aspects, which are indisputable in this case, but also in the fact that they are aimed at processing refractory concentrates, tailings storage facilities and off-balance ores containing hundreds of millions in monetary value.
The Soviet Union was the leader in developing a biotechnological approach to processing gold-arsenic concentrates from various deposits; however, the first biotechnological plant was built in South Africa in 1986.
The first semi-industrial plants in world practice demonstrated, on average, a 60% increase in gold recovery during testing. Today, more than 32 tonnes of gold per year are produced worldwide using this particular method.
The extensive practical experience of operating industrial biotechnological gold-mining plants abroad has demonstrated high economic efficiency through reduced capital investment and lower operating costs, while increasing gold recovery and environmental performance.
In April 2002, Altyn i Aymak CJSC (Ust-Kamenogorsk) obtained the first ingot of Kazakh gold from "refractory" ores that could not be processed using conventional technologies, by means of bacterial enrichment. Considering that Kazakhstan's subsoil contains gold, platinum and other precious and rare-earth metals worth hundreds of millions of dollars, but that these resources are inaccessible through conventional processing methods, there are every reason and justification to pay attention to non-traditional innovative methods and technologies. This is particularly important if these technologies meet not only the requirements of the times but also the State Strategy concerning innovation, the economy, ecology, energy and other areas.
Oil Production Industry
Biotechnological methods for developing new approaches to enhanced oil recovery constitute an urgent task, since it is well known that existing methods of developing oil fields make it possible to extract no more than 50% of the oil from the subsurface. These enhanced oil recovery methods attract attention due to their low capital intensity, efficiency and environmental safety.
Biotechnologies are based on the physiological and biochemical characteristics of microorganisms introduced into the reservoir: their ability to grow across a wide range of temperatures, pressures and salinity levels, under aerobic and anaerobic conditions, using oil as a source of nutrients for their vital activity. At the same time, microorganisms produce various metabolites: gases, acids and surfactants, generated as a result of microbiological synthesis directly within the reservoir, which ensures cleanliness and increases oil recovery by up to 40%.
The application of biotechnology makes it possible to increase the reserves brought into development by 5–7%, increase well productivity by 1.5–2 times, and increase current oil production by 15–25%. Taking into account rising energy prices, biotechnological methods pay for themselves within 1.5–2 years.
However, the most pressing issue related to oil production concerns the elimination of crude oil spills, both at oil fields and far beyond them, on land as well as in the waters of water basins. At present, chemical pollution of the environment, including pollution by oil and its refined products, poses a particular danger due to the enormous scale of extraction, transportation and processing of these energy resources. The threat of large-scale pollution has stimulated the development of methods to combat oil contamination. Recently, increasing attention has been paid to the microbiological method. The indisputable advantages of this method are its effectiveness, cost-efficiency, environmental safety, technological flexibility and the absence of secondary pollution.
An economic assessment of the use of plant-based sorbents showed that the cost of the sorbent is USD 0.75/kg, while the cost of cleaning 1 square metre of water surface amounts to USD 0.16–0.33. This is considerably cheaper than existing alternatives. However, it should be noted that all the alternatives, as well as the calculations presented by the authors, were produced abroad. In Kazakhstan, these figures may be sufficiently lower, even if not substantially so.
At present, there is no single method for completely eliminating oil pollution from either water surfaces or land surfaces. Sorption methods based on chemically neutral materials make it possible to address the problems of oil removal using environmentally friendly methods. Oil-absorbing sorbents can be used both in wastewater treatment and at all stages of combating oil spills.
A new area in the disposal of oil-refining waste is the development of an energy-generating installation by scientists at the University of Massachusetts, in which electricity is generated by bacteria. Any organic waste can be used as fuel, including waste from oil processing. The design of the device is simple; the only unusual feature is the type of bacterium, whose existence became known relatively recently. Completely decomposing hydrocarbons without any need for oxygen, these bacteria release electrons as a "by-product of their vital activity". The disposal of oil-refining waste with the generation of electricity in such an environmentally friendly installation appears more promising than burning it in furnaces.
Biotechnology in Energy: Biogas
The issue of the depletion of natural hydrocarbon reserves as energy resources did not arise yesterday, nor did the search for new energy sources begin yesterday. Numerous projects involving photovoltaic batteries, solar heaters, small power plants based on wind energy and biothermal waters, and developments aimed at using biomass as a renewable energy source are projects dating back to the 1970s.
Today, the idea of using renewable resources, namely biomass, remains relevant. Considering that plants annually fix approximately 30 billion tonnes of carbon through photosynthesis, while the amount of oil consumed worldwide is ten times smaller, there is certainly something to think about.
As for expanding the energy base through biological resources, this is possible only through a systematic approach and a thorough assessment of specific conditions. The most optimal way to use biomass is its gasification, followed by combustion in gas turbines. Preliminary calculations conducted at Princeton University show that turbogenerators operating on biomass gasification products can successfully compete with conventional thermal, nuclear and hydroelectric power installations. In the near future, the most promising areas for the application of such turbogenerators may be sectors of the economy where large quantities of biomass accumulate (in particular, sugar and distillery plants processing sugar cane). Thus, in Brazil, the use of biomass from distillery enterprises generates such a significant surplus of electricity that selling it makes alcohol cheaper than oil. Sugar cane alone can produce 50% of the energy currently generated by all sources in 80 developing countries where this crop is cultivated.
Nevertheless, there is a method of directly producing biological fuel through bacterial fermentation that has proved sufficiently profitable. This is the process of converting agricultural waste into methane, which is called biogas according to the method of its production. Biogas plants—anaerobic digesters—were developed on the basis of using communities of anaerobic methane-producing bacteria (on a global scale, these bacteria are the only source of biological methane on Earth).
In agricultural production, where there is a constant shortage of organic fertilizers in crop farming, the endless mountains of waste at livestock farms can solve the problem of raw materials for biogas production, while the processed raw material can address the shortage of fertilizers, waste disposal problems and provide electricity. Manure processed into biogas is also ideal as a fertilizer because seeds that entered animals' stomachs during feeding do not germinate in it, whereas ordinary manure generally produces weeds that infest fields.
The technology for obtaining biogas is based on anaerobic biotechnology, that is, the fermentation of organic matter of plant origin in conditions of complete absence of oxygen (in anaerobic digesters). Throughout the world, biogas is attracting increasing interest as a source of non-traditional energy resources. National programmes for the production and use of biogas have been established in all Western European countries.
Modern technical bioenergy has two main areas for converting organic waste into technically convenient types of fuel and energy:
- thermochemical conversion (direct combustion, pyrolysis, gasification, liquefaction, synthesis);
- bioconversion (production of alcohols, hydrogen, biogas, organic acids and vegetable oils).
Biotechnology in Chemistry
By the end of the twentieth century, global production of synthetic plastics had reached 130 million tonnes per year. One of the rapidly developing areas of plastic use is packaging. As early as 1975, polymers had moved into third place, after glass, paper and cardboard, in terms of their use for packaging.
Of all plastics produced, 41% is used in packaging, and 47% of this amount is used for food packaging. While glass containers generally remain within the consumer cycle and paper decomposes under natural conditions, packaging made from synthetic polymers, which accounts for 40% of household waste, is practically "eternal"—it does not decompose. Consequently, the question of what to do with plastic waste is becoming a global environmental problem.
The environmental situation in the world and, apparently, the pace and directions of development of synthetic plastic production in the twenty-first century will depend to a considerable extent on resolving the issue of plastic waste. Otherwise, humanity will bury itself in plastic waste.
With the development of biotechnology, technologies for producing packaging materials are also developing, and the functions of packaging itself are expanding. From being an inert, indifferent barrier between a food product and the environment, packaging is increasingly becoming a factor of production, since it can be used to:
- deliberately change the composition of a product. In this case, biologically active materials with immobilized enzymes are used to manufacture the packaging;
- protect food products from microbial spoilage, thereby extending their "life". For example, the shelf life of sausage products in an "active" casing increases by 2–3 times;
- create an optimal gaseous environment inside the packaging, which is widely used when storing food products in a modified and controlled atmosphere;
- regulate the temperature of food processing under microwave heating conditions.
This area is of unquestionable interest, since introducing an additive not into the food itself but into the matrix of the polymer casing makes it possible to prolong the additive's effect by regulating the rate of its mass transfer into the food product. An important advantage of such packaging is that, due to the immobilization of additives, their migration into the food product is minimized, since according to the latest data many food additives pose a certain threat to health.
Biotechnology and the Environment. Environmental Problems in Kazakhstan
Kazakhstan has a very vulnerable natural environment. The territory of the republic consists mainly of steppes, semi-deserts and deserts. There are unique inland seas and lakes, such as the Caspian Sea, the Aral Sea, Lake Balkhash, Lake Zaysan and Lake Alakol.
As a result of anthropogenic pressures, the natural environment's inherent ability to ensure the country's future economic and social development has been disrupted across virtually the entire territory of Kazakhstan.
The extensive development of agricultural production has left its mark in the form of land degradation and impoverishment of landscapes. More than 60% of the country's territory is subject to severe desertification, which leads to a decrease in soil fertility and, consequently, to reduced productivity in livestock and crop farming. Within the lifetime of one generation, the area of the Aral Sea has almost halved. Lake Balkhash faces a similar fate. With the republic's annual water demand amounting to 100 cubic kilometres, the current available water supply is 34.6 cubic kilometres. In terms of water availability per capita, Kazakhstan ranks last among the countries of the Commonwealth of Independent States (CIS).
More than 200 million cubic metres of polluted wastewater are discharged into the republic's surface water bodies annually. More than 3,000 groundwater pollution sites have been identified, with affected areas ranging from several to hundreds of square kilometres.
Most enterprises in the processing and energy sectors have imperfect technologies and morally and physically worn-out fixed production assets, which contribute to an increase in harmful emissions. Intensive pollution of air, water and soil, degradation of animal and plant life, and depletion of natural resources have led to the destruction of ecosystems, desertification, significant losses of biological and landscape diversity, and increases in morbidity and mortality among the population. The consequences of such changes include a decline in the quality of life of the population and unsustainable development of the republic. At the same time, government expenditure on environmental protection remains the lowest among the countries of Eurasia. It amounts to no more than USD 0.5 per person per year.
Biotechnology puts everything at the service of humanity and environmental protection, from bacteria to ferns (the ability of ferns to accumulate arsenic compounds), from ferns to higher plants and to everything that may seem no longer necessary to humans.
If the global market for environmental protection technologies is currently estimated at USD 235 billion, according to some estimates, biotechnology accounts for 25–40% of it.
Soil, Water Bodies and Landfill Remediation, Phytoremediation and Bioremediation
At present, the issue of cleaning soils contaminated with heavy metals and other elements remains unresolved. The phytoremediation method for removing metals from soil through their accumulation by plants is an alternative to existing soil restoration methods (excavation, washing), particularly because of its low cost. This is especially important for mountainous areas with sparse vegetation, since it also improves the landscape. At average soil concentrations of lead (Pb), zinc (Zn) and cadmium (Cd) of 4431, 4920 and 37 mg/kg, respectively, the concentrations in plant samples were relatively high (see Table 4). Thus, Chenopodium album L., growing under natural conditions, accumulated up to 557 mg/kg of Pb in its dry stems. The planted Atriplex leucoclada contained the highest amounts of Zn and Cd—3165 and 14 mg/kg of dry stems, respectively.
Vegetation reduces the spread of heavy metals through wind erosion, removal by rainwater and infiltration. The cultivated plants can be processed using conventional methods or placed in small volumes.
Other applications have also been found for the accumulation of metals by plants, such as mineral exploration and prospecting, phytoarchaeology and rhizofiltration.
Some of the most pressing environmental problems facing humanity are soil remediation, the cleanup of military testing grounds and the destruction of chemical weapons.
Accumulation of Metals by Plants
Table 4
| Plant samples | Stems | Roots | ||||
|---|---|---|---|---|---|---|
| Pb | Zn | Cd | Pb | Zn | Cd | |
| Atriplex leucoclada | 400.8 | 3165.0 | 13.9 | 189.4 | 590.0 | 1.4 |
| Chenopodium album L | 557.7 | 2186.7 | 9.6 | 194.0 | 680.0 | 3.1 |
| Eleagnus angustifolia L | 428.1 | 1372.5 | 8.5 | |||
| Haloxylon articulatum | 186.4 | 1495.0 | 9.4 | 250.2 | 800.0 | 1.6 |
| Polygonum arenas trum | 136.2 | 1590.0 | 5.6 | 271.8 | 890.0 | 2.9 |
| Salsola volkenssi | 223.7 | 1468.0 | 6.4 | 136.7 | 598.0 | 3.9 |
| Tamarix sp. | 497.6 | 2120.0 | 9.2 |
As regards the problems of destroying chemical weapons and cleaning up military testing grounds, the United States has a special university-level training programme for military personnel that includes familiarization with methods of bioremediation of soil, water bodies and air. In 2001, three major US Department of Defense testing grounds purchased DARAMEND@, a microbial bioremediation technology developed by W.R. Grace & Co., for treating soil contaminated with explosive substances, since this technology demonstrated 99% soil purification after just the first two treatment phases.
In Russia, research organizations, including defense-related organizations, are developing biotechnological methods (using microorganisms and plants) for soil remediation and the processing of reaction masses and liquid waste generated during the detoxification of chemical weapons. A biotechnological system for purifying air from organic compounds has also been developed, and a pilot installation has been created. Licences for its use have currently been acquired by chemical enterprises in the United Kingdom and Finland.
Recent decades have been characterized by the release into the environment of enormous quantities of synthetic organic compounds (xenobiotics) of various structures, which are often toxic to living organisms. Some xenobiotics accumulate in the environment due to a certain lag in the evolutionary processes of microorganisms aimed at developing their ability to perform catabolism, that is, to degrade these compounds. The current task is to make maximum use of the potential of microorganisms, which possess an enormous diversity of enzymes capable of carrying out the degradation reactions of various xenobiotics. The use of this potential is what is known as "bioremediation".
Today, up to 30% or more of the cost of industrial production is accounted for by the construction of wastewater treatment facilities. Existing wastewater treatment methods are constantly being improved; however, their effectiveness does not always meet environmental requirements. A way out of this situation is to revise traditional industrial technologies in order to create zero-waste production facilities with a closed cycle of liquid flow utilization. In addressing this problem, the leading role belongs to local biological treatment technologies that return wastewater purified to the required standards to the technological cycle or obtain useful biological products from wastewater.
Only biotechnological methods have a number of advantages compared with physicochemical methods: environmental safety of processing, harmlessness of the final disposal products to the environment, high adaptability and specificity with regard to various pollutants, acceptable labour intensity and cost of work, and preservation of the natural condition and fertility of reclaimed soils.
§ 3. Main Prerequisites for the Development of Biotechnology in Kazakhstan
§ 3.1. Assessment of Existing Supply and Demand for Biotechnological Products in Kazakhstan
At present, the development and production of biotechnological products in our country have not achieved the required level of development. The country is dependent on imports for many bioproducts. As in Russia, a significant imbalance in the development of the biotechnology industry is observed in Kazakhstan. In Kazakhstan, industrial production of biotechnological products on a relatively large scale is represented by the production of certain types of medicinal products, alcohol and dairy bioproducts.
Pharmaceutical Industry
A huge influx of imported medicines enters the Republic of Kazakhstan. The volume of imports of finished medicinal products (MPs) has been steadily increasing since 2000. In 2003, 12,917.8 tonnes of medicines worth USD 269 million were imported into Kazakhstan. This was 16% and 34.2% more, respectively, than in 2002. As can be seen, the increase in the value of imported medicinal products significantly outpaced the increase in their physical volume. Naturally, this was accompanied by an increase in the average customs value of one tonne of medicinal products imported into the country (from USD 13.9 thousand in 2002 to USD 16.2 thousand in 2003, an increase of 16.5%).
The number of supplier countries increased (from 50 to 55), and their composition changed. The additional suppliers included Sweden, Argentina, Jordan, Malaysia, Bangladesh and Indonesia.
The composition of the top five countries in terms of the value of imported products has remained unchanged for several years: Germany, Russia, India, France and Hungary.
In 2005, the volume of imported medicinal products under HS Code subheading 3001 (blood preparations, other biological and immunological products, including biotechnological preparations and cultures of microorganisms) amounted to USD 556 million.
Sales of medicines in the Republic of Kazakhstan have been increasing in recent years by an average of 30% annually. The table below presents the size of the medicinal products market for 2003–2005.
The Medicinal Products Market in the Republic of Kazakhstan
Table 5
| Period | Imports | Production | Exports | Market volume | Import share |
|---|---|---|---|---|---|
| year | million USD | million USD | million USD | million USD | % |
| 2003 | 269 | 14 | 1.6 | 283 | 95.6 |
| 2004 | 390 | 20 | 2.6 | 410 | 95.7 |
| 2005 | 556 | 29 | 7.1 | 579 | 97.2 |
According to official data, in 1998 the population of Kazakhstan purchased medicinal products, including antibiotics, worth more than USD 300 million. Sales of medicinal products manufactured in Kazakhstan accounted for approximately 4% of the actual capacity of the pharmaceutical market in 1999 and 6% in 2001. The production of antibiotics for healthcare purposes has not been established in the republic, although the development of broad-spectrum and prolonged-action chemotherapeutic drugs is an urgent issue.
In 2003–2005, sales of medicinal products manufactured in Kazakhstan accounted for approximately 5% of the actual capacity of the pharmaceutical market. In monetary terms, medicinal products worth approximately USD 14 million were produced in 2003, and USD 29 million in 2005. At the same time, the production of antibiotics for healthcare purposes has not been established in the republic, although the development of broad-spectrum and prolonged-action chemotherapeutic drugs remains an urgent issue.
The table below presents data on the production of biotechnological products in Kazakhstan's pharmaceutical industry.
Production of Products in Physical Terms in the Republic of Kazakhstan
Table 6
| Product name | 2002 | 2003 | 2004 | 2005 |
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 |
Enzymes and other organic compounds, tonnes
| - | - | - | - |
|---|
Rennet and its concentrates, tonnes
| - | - | - | - |
|---|
Enzymes; enzyme preparations not included in other groupings, tonnes
| - | - | - | - |
|---|
Salicylic acid, O-acetylsalicylic acid; their salts and complex esters, kg
| - | - | - | - |
|---|
Lysine, glutamic acid and their salts; quaternary ammonium salts; phosphoaminolipids; amides, their derivatives and salts, kg
| - | - | - | - || - | - | - | - |
Lactones not included in other groupings; heterocyclic compounds containing only nitrogen heteroatoms and having an unfused pyrazole ring, pyrimidone ring, piperazine ring, unfused triazine ring or phenothiazine system of unfused rings; nucleic acids and their salts; hydantoin and its derivatives, kg
| - | - | - | - || - | - | - | - |
Chemically pure sugars not included in other groupings; simple and complex sugar ethers and their salts not included in other groupings, kg
| | 106 | | - || - | --- | - | - |
Provitamins, vitamins and hormones; glycosides and plant alkaloids and their derivatives; antibiotics, kg
| 4205 | 11892 | | - || ---- | ----- | - | - |
Other glands and organs, their extracts and other substances of human or animal origin not included in other groupings, kg
| 553 | 477 | - |
|---|
Pharmaceutical preparations, thousand tenge
| 2840268 | 3362333 | 3646877 | 4967900 |
|---|
Other pharmaceutical preparations, thousand tenge
| 544663 | 662739 | 1000829 | - || ------ | ------ | ------- | - |
Biofuel obtained from oil-bearing, sugar-bearing and starch-bearing crops, tonnes
| 152 | 83 | | - || --- | -- | - | - |
Prepared culture media for growing microorganisms, tonnes
| - | - | - | - || - | - | - | - |
Note: "-" means not produced in the Republic of Kazakhstan;
"blank" means no data available.
There are approximately 65 enterprises producing medicinal products in the republic; however, as follows from the table above, many types of biotechnological products are not manufactured in the domestic pharmaceutical industry.
Alcohol Production
The existing enzyme production capacities make it possible to expect the production of preparations in volumes sufficient to cover the needs of all alcohol plants in Kazakhstan (approximately 15 million decalitres) and to partially export enzyme preparations to the CIS (5 million decalitres). However, at present, the existing capacities are not being utilized to the required extent.
Table 7 below presents data on fermented alcoholic products.
Production of Products in Physical Terms in the Republic of Kazakhstan
Table 7
| Product name | 2002 | 2003 | 2004 | 2005 |
|---|
Ethyl alcohol and other denatured alcohols obtained from fermented agricultural products, thousand litres
| 12124.4 | 6138.5 | 5620.6 | 7300 |
|---|
Fermented beverages (apple cider, pear cider, mead); mixed beverages containing alcohol, thousand litres
| 23174.9 | 14082.5 | 9015.3 | 8928 |
|---|
Services in the production of other non-distilled fermented beverages, thousand tenge
| - | - | - | - || - | - | - | - |
As follows from the data in Table 7, the production volumes of fermented beverages have declined in recent years.
Another application of ethyl alcohol is the production of ethanol. In many countries, ethanol is used instead of environmentally harmful tetraethyl lead to increase the octane rating of fuel. Therefore, the production of highly purified ethyl alcohol (99.6%) will make a significant contribution to preserving environmental well-being, which is also particularly advantageous due to the low production cost of biotechnological products.
Production of Dairy Bioproducts
The production of enzymes used in the dairy industry has been organized in the Republic of Kazakhstan.
Table 8 presents data on bioproducts in the dairy industry.
Production of Products in Physical Terms in the Republic of Kazakhstan
Table 8
| Product name | 2002 | 2003 | 2004 | 2005 |
|---|
Yoghurt, other fermented or soured milk and cream, tonnes
| 53853 | 69599 | 76739 | 93941 |
|---|
Curdled milk and cream, yoghurt, kefir, sour cream, acidophilus milk, other fermented or soured milk and cream, tonnes
| 53009 | 68497 | 78189 | - || ----- | ----- | ----- | - |
Curdled milk and cream, yoghurt, kefir, sour cream, acidophilus milk, other fermented or soured milk and cream, unflavoured and not containing fruit, nut or cocoa additives, tonnes
| 49144 | 62606 | 70902 | - || ----- | ----- | ----- | - |
Curdled milk and cream, yoghurt, kefir, sour cream, acidophilus milk, other fermented or soured milk and cream, flavoured or containing fruit, nut or cocoa additives, tonnes
| 3854 | 5874 | 7268 | - || ---- | ---- | ---- | - |
Fermented milk and cream, yoghurt and other fermented products in powder, granules or other solid form, tonnes
| 11 | 17 | 19 | - || -- | -- | -- | - |
Inactive yeasts; other dead single-cell microorganisms, tonnes
| - | - | 6682 | 6987 || - | - | ---- | ---- |
As follows from Table 8, the volumes of dairy bioproducts show an upward trend. This is also associated with an increase in the number of companies engaged in the production of fermented dairy products, which currently number approximately 170 enterprises.
Current State of Biotechnology Science in Kazakhstan and Its Experimental and Production Base
During the Soviet period, Kazakhstan was assigned the role of a production base for industrial biotechnology. Specialized institutions were established and closed cities of strategic importance were built, forming part of the military-industrial complex. Thus, by the beginning of the 1990s, we had accumulated a foundation consisting of developed infrastructure, highly qualified personnel and a modern production base. Fifteen years were sufficient for the level of biotechnological research to decline and for technologies to become hopelessly outdated. Most scientists and specialists left for other countries, while unique and expensive production facilities were permanently shut down.
At present, the development of biotechnology in Kazakhstan is characterized by a morally outdated Soviet-style scientific and industrial base and a small number of specialist groups working in this field. The small number of specialist groups dealing with biotechnology issues leads to a lack of competition in this field, which results in a low level of scientific research. In turn, the low level of research fails to create incentives for financing scientific research. The negative effect is multiplied by the following factors:
- lack of knowledge of the English language (since the leaders in this field are the United States, the countries of the European Economic Community (EEC), Japan and other countries);
- lack of information and international cooperation;
- "authoritarian" traditions in science.
The range of biotechnological products manufactured in Kazakhstan is narrow, and the overwhelming majority of these products are oriented towards the domestic market, since they are not competitive in the open market.
The experience of establishing and operating the Progress Scientific and Production Association Technopark OJSC in the city of Stepnogorsk shows that without advanced research in the field of biology, biotechnological production does not go beyond existing, often outdated, technologies.
Nevertheless, within the framework of budget programmes, research corresponding to the priority areas of biotechnology development is being conducted in Kazakhstan. These include:
- The Programme for the Formation and Development of Biotechnological Production at the Progress Scientific and Production Association Technopark Open Joint-Stock Company in the city of Stepnogorsk for 2003–2005;
- The Republican Scientific and Technical Programme "Scientific and Technical Support and Organization of Biotechnological Product Manufacturing in the Republic of Kazakhstan" for 2001–2005;
- The Intersectoral Programme "Development of Pharmaceutical Production at the Facilities of Biokorm LLP";
- The Programme "Applied Scientific Research in the Field of the Agro-Industrial Complex".
These programmes provide for the implementation of projects in the following areas.
Biotechnological Products for Agriculture
The grain processing project envisages the production of more than 53 thousand tonnes of gluten per year. At the same time, 80% of the products are intended for export to near and far abroad countries. The total amount of financing for the project is expected to exceed USD 60 million. The estimated payback period of the project is 5 years.
Comprehensive (deep) processing of grain to obtain dry gluten, 39% starch liquid, 14% starch mixture and bran is based on the use of modern technology developed by Alfa Laval. This technology makes it possible to process even low-grade grain that has no market demand, obtaining the above-mentioned products. The results of marketing research have shown a shortage of gluten and starch, which are widely used in the food and microbiological industries and in biotechnology, not only in the markets of the CIS countries but also in Europe.
The by-products of this production—starch and bran—form the basis for all the other proposed projects. The amount of investment required for the project to organize the production of antibiotic substances is USD 39 thousand.
Restoration work to launch the production of pesticides and feed additives is nearing completion. The latter will begin production in the summer with the assistance of the French company "Odysseo-Eurasia". The establishment of a facility for processing waste from alcohol production is being completed.
Biotechnological Products for Healthcare
It is planned to establish the production of 16 preparations (antibiotics, vitamins, enzymes and proteins) at the facilities of Biomedpreparat JSC, with the intention of subsequently expanding their range to 50 items. The cost of the project is USD 5.8 million.
An increase in the production volumes of probiotic preparations is also planned: bifidumbacterin, colibacterin, lactobacterin and bifilol—to 3.1 million vials per year. The expansion of the production of proteolytic immobilized enzymes is planned:
- profezim – 7 million vials per year;
- stomatozyme – 3 million vials per year;
- imozimase or its analogue – 3 million vials per year.
Alongside its main products, Biomedpreparat JSC is planning to expand the production of disposable syringes by installing a second production line costing USD 10 million, as well as to complete work on establishing a radioisotope sterilization facility for medical preparations and products, which will require USD 750 thousand.
In the future, the production of broad-spectrum antibiotics is planned. As a result of the implementation of this project, the following production volumes are planned:
- gentamicin – 50 million vials/blisters/tubes per year;
- lincomycin – 50 million vials per year;
- rifampicin – 50 million vials per year.
The organization of large-scale production of these preparations will make it possible to halve purchases of widely used antibiotics. The production of cephalosporin antibiotics is not envisaged due to their high toxicity and the need for chemical modification of the production process.
Another area planned within the framework of the long-term phase is the establishment of production of genetically engineered preparations: human insulin – 400–600 kg per year, interleukins, interferons and somatotropin. In the former USSR, within the framework of the genetic engineering production programme, laboratory and pilot-industrial production regulations were developed at Biomedpreparat JSC for recombinant human insulin, which was not inferior in quality to the product manufactured by Eli Lilly. This area should be implemented jointly with Russian enterprises under the auspices of the Coordinating Council of CIS States, within the framework of a unified plan of investment measures in medicine and healthcare.
The final area belonging to the long-term phase is the organization of production of dry nutrient media for the isolation and identification of microorganisms used in microbiology and biotechnology. The cost of the project is USD 2.5 million.
In addition, work is being carried out jointly with the Bekturov Almaty Institute of Chemical Sciences to introduce a new technology for the production of nicotinic acid and anti-tuberculosis drugs. Design and engineering documentation has also been developed for organizing the production of carbon dioxide extracts and halogen preparations.
Production of the medicinal preparation imozimase. Imozimase is a highly purified proteolytic enzyme widely used in the treatment of purulent-inflammatory processes and wound surfaces.
Tableting of phytopreparations and other medicinal products for healthcare purposes based on domestic substances. Arglabin, salsocolin and other original preparations so essential for patients will be more accessible to consumers in tablet form.
Biotechnological Products for the Processing Industry
The industrial production of highly purified ethyl alcohol is a product that is in demand, economically profitable and environmentally safe.
As a result of reconstruction, the mash rectification unit was replaced, making it possible to obtain higher-quality ethyl alcohol of the "Lux" and "Extra" grades, which are in increased demand on the market.
Production of purified enzymes: Glucavamorin G18 and Amylosubtilin G18. Glucavamorin and Amylosubtilin preparations are used together in the alcohol industry for the saccharification of starch-containing substrates.
The main purpose of using enzyme preparations in alcohol production is to eliminate the need for scarce malt grain, ensure the stability of the wort fermentation process and, ultimately, reduce the cost of alcohol.
Reconstruction of ethyl alcohol production with optimization of the fermentation process and organization of a solvent production facility.
Projects for organizing large-scale production of technical ethanol for the oil-refining industry are currently under development.
§ 3.2. The Relevance of Biotechnology Development in Kazakhstan
The Need to Develop and Implement Standards, Rules and Conditions for Authorizing the Consumption of Biotechnology Products in the Republic of Kazakhstan
The high profitability of the bioindustry may become a reason for pursuing excessive profits at any cost. Therefore, it is necessary to bear in mind that biotechnologies, on the one hand, are a powerful instrument of progress, while, on the other hand, their careless and indiscriminate use may have negative consequences. Today, the following opinions exist worldwide on this issue.
In the United States, a product is considered safe for consumption until it has been proven to be risky. In the European Union (EU), conversely, consumption is considered risky until it has been proven to be safe.
The environmental organization GREENPEACE insists on banning the use of genetically modified plants for food and feed purposes, since it is not yet known what impact these products may have on human health in the event of their long-term consumption.
A number of countries impose strict requirements on the labeling of products containing GM (genetically modified) components. In addition to the EU, these countries include Japan, the Republic of Korea, Australia and New Zealand.
Regardless of whether Kazakhstan develops its own biotechnologies or not, under conditions of globalization, the Republic will be drawn into the consumption of products from the global bioindustry. Kazakhstan must not become an experimental laboratory for the developed countries of the world.
In order to prevent negative consequences, reliable protection must be established. To this end, Kazakhstan needs to have highly qualified services responsible for monitoring and controlling the use of imported and domestic biotechnology products.
When developing priorities for biotechnology development, Kazakhstan must take into account the established characteristics and development prospects of its economy:
the high share of the agro-industrial complex and the mining industry;
the availability of natural resources and plans for the development of the Caspian shelf, taking into account the need to maintain the ecological balance in nature;
the continued high rates of economic growth and the prospects for developing petrochemicals, construction, the transport and telecommunications complex, information technologies, the textile industry, tourism and sports;
proximity to rapidly growing and promising sales markets (the countries of Central Asia, China, India and Russia);
the availability of developed infrastructure in the field of nuclear physics (Institute of Nuclear Physics, the city of Kurchatov) and space exploration (Baikonur Cosmodrome, the city of Priozersk);
the availability of the legacy of Soviet science (the Republican Collection of Microorganisms, the Technopark of the Scientific and Production Association "Progress", biological research institutes and others).
For the Republic of Kazakhstan, which is an agrarian country, the development of technologies and the production of feed additives in the field of agricultural biotechnology are important. The development of animal husbandry has been and remains a strategic direction of the agro-industrial complex in the Republic. The number of livestock and poultry in the Republic of Kazakhstan has increased noticeably in recent years.
Livestock and Poultry Population in the Republic of Kazakhstan, thousand heads
Table 9
Download
| || - |
Name of animals
| 2000 | 2001 | 2002 | 2003 | 2004 | 2005 |
|---|---|---|---|---|---|
Cattle
| 4107 | 4294 | 4560 | 4878 | 5181 | 5440 | |
|---|---|---|---|---|---|---|
| Sheep and goats | 9981 | 10479 | 11273 | 12247 | 13282 | 14275 |
| Pigs | 1076 | 1124 | 1230 | 1369 | 1341 | 1313 |
| Horses | 976 | 990 | 1019 | 1064 | 1110 | 1160 |
| Camels | 98 | 104 | 108 | 115 | 123 | 128 |
| Poultry | 19706 | 21130 | 23791 | 24823 | 25481 | 25325 |
Taking the established trends into account, the demand for feed additives will increase by 25–30% in the coming years.
As for the plans to develop the Caspian shelf, the development of oil fields on the shelf of the Caspian Sea and the anticipated increase in oil production volumes, and consequently the associated increase in oil losses, may lead to an increase in the oil content of the coastal waters of the Kazakhstan sector of the Caspian Sea. This, in turn, will entail environmental, economic and social problems.
The oil and gas industry ranks first among industrial sectors in terms of investment volume. Despite this, in the main oil and gas production and oil refining areas — the Atyrau and Mangystau Regions — operations are carried out using outdated technologies and obsolete equipment, which leads to accidents and oil leaks.
According to expert estimates, if oil losses during production, transportation and processing range from 1.5% to 15%, the estimated recoverable reserves of Kashagan oil give rise to alarming forecasts regarding oil pollution. The practice of burning associated gas in flares also causes significant environmental and economic damage. The increased thermal background and acidification of environmental components around the fields resulting from gas combustion have a negative impact on the soil, vegetation and wildlife in areas adjacent to oil complexes, making their own "contribution" to the increase in the greenhouse effect. Irrecoverable gas losses amount to more than 740 million m³ per year. A dependence has been identified between the increased incidence of disease among the population in the area of the Tengiz oil and gas field (more than 6 times higher than regional indicators) and atmospheric air pollution with sulfur and nitrogen dioxides.
Today, the issue of production waste at oil fields is particularly acute. With the growth of oil production, a new problem has emerged — the accumulation of large volumes of sulfur. For example, more than 7 million tons have already accumulated at the Tengiz field alone. The environmental impact of this sulfur has not yet been assessed; only today has work begun on processing sulfur into granules for subsequent sale abroad.
As a result of the rise in the level of the Caspian Sea, more than 200 wells and oil fields, including the largest ones — Kalamkas and Karazhanbas — were flooded. This poses a threat not only to biological diversity (90% of the world's sturgeon reserves are concentrated in the Caspian Sea, along with a large number of bird species and the endemic Caspian seal), but also to the entire ecosystem of the Caspian Sea.
Depending on the time elapsed between an emergency oil spill and the commencement of cleanup operations, either the entire set of measures or individual components thereof is implemented. However, the use of oil-absorbing sorbents is advisable at practically all stages. Oil-absorbing sorbents are being developed in many countries, but specialists are increasingly focusing their attention on the development of sorbents made from plant waste. First and foremost, this is due to their environmental safety resulting from their natural origin and the simultaneous resolution of the problem of agricultural production waste disposal.
As a result of the activities of enterprises in the mining and metallurgical complex, more than 20 billion tons of industrial waste have accumulated in Kazakhstan, with approximately 1 billion tons added annually, including 230 million tons of radioactive waste. 95% of the total volume of extracted ore ends up as waste, which is often extremely toxic and placed in locations unsuitable for storage. Available statistics indicate an increase in toxic waste. Over the past four years, its annual generation increased from 92 million tons to 150 million tons in 2002, or by a factor of 1.6. This waste is concentrated predominantly in the Karaganda Region — 29.4%, East Kazakhstan Region — 25.7%, Kostanay Region — 17% and Pavlodar Region — 14.6%. The lands of the Kyzylorda, Atyrau and West Kazakhstan Regions are also contaminated with heavy metals and petroleum products. Here, the volumes of abandoned and buried drilling mud, oil-contaminated and low-radioactivity waters, and the areas of disturbed land are difficult to assess.
An environmental catastrophe threatens Aktau and the Caspian Sea. The factories of the industrial giant, the Caspian Mining and Metallurgical Combine (CMMC), discharged wastewater into a depression located just a few kilometers from the city of Aktau, where the artificial Lake Koshkar-Ata was formed. These factories were primarily engaged in uranium enrichment. Over time, practically all the elements of the periodic table accumulated in the Koshkar-Ata water body, including radioactive and toxic substances.
Lake Koshkar-Ata and the Caspian Sea are separated from each other by a narrow coastal strip no more than 8 km long. Therefore, the danger arose that the Caspian Sea could be contaminated by water from the Koshkar-Ata storage reservoir.
In addition to the pollution of the Caspian Sea, there is a danger of contamination of the groundwater of the Kuyulus technical water deposit, from which the Mangyshlak Atomic Energy Combine (MAEC) obtains part of the water supply for Aktau.
However, apart from the contamination of groundwater with toxic and radioactive substances, there is another problem associated with the Koshkar-Ata storage reservoir. At present, the lake is drying up because the factories of the former CMMC are idle and no longer discharge water. Toxic dust forms on the dried-up shores of the lake and is carried by the wind throughout the surrounding area.
Environmentalists in Mangystau face a difficult problem. If the previous water level in the lake is maintained, toxic waste may be discharged into the Caspian Sea. If the lake is allowed to dry up, dust will contaminate all the lands and pastures around Aktau and the settlement of Akshukur.
The constantly increasing volumes of industrial production waste are creating new technogenic landscapes; as the height of dumps and spoil heaps increases, they become sources of intensive dust formation.
The second place in terms of production waste volumes after the mining industry is occupied by the metallurgical industry and the energy sector. More than 1.5 billion tons of waste have accumulated in the ash dumps of the Ekibastuz State District Power Plant in the Pavlodar Region alone. The ash storage facility of the Sogrinskaya State District Power Plant is under the threat of a breach into the Irtysh River.
More than 350 waste storage sites have been created by the largest corporations, OJSC "Ispat Karmet" and "Kazakhmys", in the Karaganda Region. The long-term waste of the Balkhash Mining and Metallurgical Combine has led to the contamination of the shores and waters of Lake Balkhash.
The Nura River is notorious for its bottom sediments containing metallic mercury. For 20 years, wastewater from the production association "Carbide" and other factories in the city of Temirtau, as well as ash from the Karaganda State District Power Plant No. 1, has been discharged into it. The ash absorbed mercury from the wastewater, and today, over a stretch of 25 km along the channel and floodplain of the Nura River, silt deposits containing mercury have formed. As a result, the entire system of lakes of the Korgalzhyn State Nature Reserve is under threat, for which this river is the only supplying watercourse.
Vast territories of Kazakhstan have suffered from the activities of military test sites and space launches. Between 1949 and 1991, 470 nuclear explosions were conducted at the Semipalatinsk Nuclear Test Site. It is impossible to calculate the exact number of people who died; the number of people exposed to radiation reached half a million. Approximately 2 million hectares of agricultural land within the territory of the former Semipalatinsk Nuclear Test Site are subject to radioactive contamination.
The Aral and Semipalatinsk regions have been declared ecological disaster zones, where natural ecological systems have been destroyed, flora and fauna have degraded, and significant harm has been caused to public health as a result of the unfavorable environmental situation. Ecological disaster zones pose a real threat to the country's internal security.
Currently, in the areas adjacent to the former Semipalatinsk Test Site (85 settlements with a population of 71.9 thousand people), high levels of cancer incidence and mortality, diseases of the circulatory system, congenital abnormalities among newborns and premature aging effects are observed among the population.
In the ecological disaster zone of the Aral Sea region (178 settlements with a population of 186.3 thousand people), high levels of gastrointestinal diseases and anemia are observed, especially among women and children, as well as high child mortality and congenital pathologies.
Currently, four military test sites and the Baikonur complex operate on the territory of the Republic of Kazakhstan. Fallen and falling rocket fragments, spills of highly toxic fuel and other factors that have a negative impact on the environment and the population living in the immediate vicinity pose a real environmental threat. Rocket launches from the Baikonur Cosmodrome are supported by the availability of drop zones for separating rocket components, with a total area of 12.24 million hectares.
Under these conditions, environmental assessment plays an important role in addressing the problem of preventing and eliminating technogenic impacts at sites where space equipment, military equipment and military facilities are produced, tested, stored and operated, as well as at the locations of industrial organizations and military units and formations engaged in rocket and space activities.
Currently, research work is being carried out under the budget program "Monitoring the Environmental Condition of Areas of the Territory of the Republic of Kazakhstan Subject to Rocket and Space Activities". In addition, within the framework of the Program for the Development of the Resource Base of the Country's Mineral Resource Complex for 2003–2010, comprehensive hydrogeological and geoecological studies of the territories of military test sites have been initiated. Since there is no alternative to space technologies in solving a number of tasks, reducing the impact of rocket and space activities on the environment and public health, and ensuring the environmental safety of rocket and space complexes are becoming increasingly relevant.
Life in the atomic and chemical world has become more comfortable, but at the same time it has acquired additional elements of risk associated with radiation, environmental pollution by toxic compounds and the potential danger of chemical weapons. In addition to humans, our planet is home to an enormous diversity of other living organisms that are also exposed to the aforementioned negative impacts and risks. Many problems associated with the state of the environment are, by their nature and essence, environmental problems. In this regard, the tasks of modern biology include identifying and detecting stress factors in natural ecological systems, restoring these systems and creating conditions for the functioning of sustainable ecological systems. Therefore, over the past decade, scientists have focused their attention on rapidly developing biotechnology methods that make it possible to solve various environmental problems.
The achievements of biotechnology are not only widely used for environmental protection purposes, but everything associated with biotechnology is primarily aimed at protecting human health and ensuring environmental well-being.
§ 4. A Retrospective Historical Review of the Development of the System for Organizing Science in Kazakhstan
Since the existing Kazakhstani biotechnology school is a legacy of the old Soviet system of organizing science, it seems necessary, in order to understand its essence, to compare the old Soviet system with modern advanced systems around the world.
The broadest classification of economic systems divides them into two fundamentally different types — administrative-command (centralized) and market (decentralized) systems. In the latter, all economic entities, including the state, are equal.
Since science and production in the field of biotechnology are subsystems of the economy, they are practically entirely determined by the adopted economic paradigm. Accordingly, two different concepts can be identified — the administrative-command (AC) concept and the market concept.
Historical experience makes it possible today to describe the qualitative differences between these two systems and analyze their advantages and disadvantages.
The most important economic, social and organizational characteristics of the system in the USSR economy were dictated by the fundamental principles of the paradigm adopted at that time: complete nationalization of property created in social production, including intellectual property; closedness and reliance on one's own resources; a mobilization-based development model and excessive militarization of the national economy; and the ideologization of all types of activity, including the scientific and technical sector. As a result, the system of science and production in the AC economy had a number of unique characteristics:
1) organization: an organizational and management scheme was used: departmental organization and centralized management of all entities engaged in research, development, production and maintenance;
2) main entities: these consisted exclusively of large and extra-large research and development organizations, design organizations and experimental production facilities (employing hundreds and sometimes tens of thousands of people), which were under the management (in fact, under the complete subordination) of the relevant ministry or department. In such schemes, the linear model of innovation processes did indeed operate to a first approximation; that is, new knowledge generated as a result of fundamental research (in the relevant research institutes (RIs)) was transferred in a planned manner to applied research institutes, design bureaus (DBs), pilot plants and further on, up to the organization of production of new products. In this
scheme, the actual needs of the end consumer were not so much studied as they were "modeled". Moreover, they were often disregarded in favor of the interests and capabilities of the consumer.
Due to departmental organization, such a scientific system involved the alienation of the vast majority of producers of new knowledge, that is, entities in the R&D sector, from both the education sector and industry.
In an innovation system (IS) of this type, due to the adopted social paradigm, legitimate (officially included in the innovation process) small-scale forms of innovation activity were completely absent; that is, small innovative enterprises were absent, as was business in general;
3) management, including incentives and motivation: in the planned economy, all processes, including the innovation process, were regulated centrally in accordance with the parameters of the national economic plan. The "Center" (the State Planning Committee, ministry or department) determined the procedure and structure for updating technologies, products and services for consumers and carried out their planned "implementation" in the relevant organizations. State resources were allocated centrally for the implementation of these tasks.
The absence of private ownership rights to intellectual products created by individual inventors made it impossible to use powerful motivational mechanisms in the innovation process;
4) some qualitative characteristics: the administrative-command system, due to the fundamental principles of its structure, was characterized by low personnel mobility, both horizontal (intersectoral and interregional) and vertical. In general, this type of system is characterized by low flexibility and mobility of all structures, including, for example, the thematic structure of research and development. This became one of the main reasons for the USSR's lagging behind in the technological innovation race that unfolded among industrially developed countries in the second half of the 20th century.
The orientation of the incentive system in the planned economy toward "gross" indicators (that is, quantitative indicators of the volume and scale of activity), to the detriment of qualitative indicators, together with the low speed of response to the rapidly changing needs of the innovation sector of the economy itself, led to a constant shortage of modern instruments and unique (non-mass-produced) equipment. They were replaced by relatively cheap labor resources, including intellectual resources. As a result, an important characteristic of the innovation process was an excess of labor at all stages of the cycle. This often led to the emergence of a labor "ballast" in many entities.
The administrative-command system model described above also had certain (in some respects unique) advantages. For example:
the ability to concentrate enormous intellectual and material resources to solve large-scale scientific and technical tasks required by the state;
highly favorable economic and social conditions for the development of fundamental and exploratory research from the perspective of the scientific community itself;
the ability to solve certain complex problems with very modest resources (through the use of inexpensive intellectual resources).
At the same time, by the late 1980s and early 1990s, the irreparable shortcomings inherent in the administrative-command model of the innovation system had become clearly visible. The main ones were:
the closed and non-transparent nature of the system and, as a consequence, the absence of a real connection between public needs and the priorities of scientific and technical policy;
excessive centralization of management, very low mobility and flexibility of the system, and low efficiency in the use of resources.
All this led to the USSR's increasing lag behind in the most advanced areas of science, technology and high-tech production and, ultimately, to its defeat in the technological race.
In this regard, the innovation system that emerged in post-Soviet Kazakhstan can be considered a system in transition.
Since 1992, Kazakhstan has begun its transition to a market-based economic model. Two important political decisions were implemented — the openness of the public system and the denationalization of the economy. At the same time, under the influence of both the decisions adopted by the state and the actions of non-state entities, a new market-oriented scientific and production system began to take shape. Significant changes occurred in one of the main entities of the innovation process — the Kazakhstani science sector. These changes affected the following characteristics.
Scale and General Situation.
Labor resources and financial support decreased several times over. The scope of research narrowed significantly, and entire fields (and organizations) disappeared due to their lack of competitiveness. The overall situation is characterized by limited and underdeveloped state funding for scientific and innovation activities, limited financial markets, the absence of a sufficient number of large companies willing to invest in technological innovations, and a lack of initial capital. As a result, all this constrains innovation activity.
Political and Ideological Restrictions.
The principle of openness and integration of domestic science into global science has largely been implemented. Thousands of our scientists and engineers work abroad and participate in international and joint projects. Research organizations and individual teams carry out work worth tens of millions of dollars for foreign clients. Ideological barriers in science have disappeared.
Legislative Framework.
The foundations of a legislative framework have been established; however, there are entire groups of pressing issues that require new laws and other regulatory legal acts, as well as amendments to existing ones. These include, for example: innovation activity; intellectual property created using budget funds; the integration of science and education; and a number of other issues. In general, indirect regulation (taxation, customs and depreciation policies) is neutral toward high-tech sectors, although under the conditions of the adoption of an industrial and innovation strategy, it should have been stimulating.
Organizational Structure.
The organizational structure of science is changing, although very slowly: the size of old scientific organizations has decreased significantly (several times), which has increased management flexibility and quality. New sectors have emerged, primarily in applied non-state science and small innovative businesses.
Qualitative Characteristics.
The availability of instruments and equipment has not improved, but the differentiation between strong and weak organizations has increased. Science has aged considerably; however, over the past three years, young people's interest in natural science and technical universities has increased somewhat. Science and education are converging very slowly. Solving this problem could provide a qualitatively new impetus to the revival of domestic fundamental science and the development of applied science.
With rare exceptions, management in science is completely inadequate for the new economic realities. There is no innovation culture in universities and scientific organizations. Innovations are created primarily based on the logic of scientific development rather than public needs and demand (that is, the "technology push" approach dominates).
Budget funds are used inefficiently. One of the reasons is outdated funding mechanisms (the basic funding principle) and an archaic system for organizing scientific activities, in which traditional Soviet-style departmental institutes continue to dominate. At the same time, production and technological infrastructure and information infrastructure are underdeveloped, while many processes are excessively bureaucratized (licensing, certification and patenting). All this indicates that Kazakhstan currently has a transitional-type innovation system in operation, combining elements of the old administrative-command system and the new innovation system characteristic of market economies. The existing institutions and organizations in the biotechnology sector also belong to the administrative-command part of the IS.
The market innovation system includes scientific and technical organizations in the private sector of industry and services ("in-house science"); small innovative enterprises; and numerous non-state, non-profit scientific, analytical, consulting and other centers. The potential of the Kazakhstani scientific diaspora working abroad also belongs here.
All these entities of the innovation system operate according to the organizational and systemic principles of a market economy. Moreover, some of them are effectively elements of the global innovation system.
In the "new" part of the Kazakhstani innovation system (the market-based part), the most acute and clearly visible problems are the absence of a critical mass of small innovative enterprises and the necessary innovation infrastructure.
In the "old" biotechnology science sector, the most acute problem is the preservation of Soviet-style institutes financed according to the principle of "supporting the entire network of organizations". This means that science continues to implement a "job preservation" strategy rather than a strategy of effective development.
§ 5. Analysis of Problems Hindering the Growth of Commercialization of Scientific and Technical Developments in Biotechnology in Kazakhstan and Worldwide
Biotechnology makes it possible to rapidly transform new knowledge obtained through fundamental research into capital that provides a powerful impetus for the development of various sectors of the economy. The application of biotechnological approaches to the creation of new industries or the modernization of existing ones makes it possible to achieve a significant increase in the efficiency of investments of financial and other resources. It is precisely the use of the latest achievements in biotechnology in production that makes it possible to achieve exceptionally high economic indicators.
In many cases, biotechnologies are more efficient and resource-saving than traditional technologies. However, since they differ significantly from traditional technologies, their implementation can only be expected in the long term.
Technology commercialization is the process of transforming the results of scientific and technical activities into commodities and their effective sale on an industrial scale. In this regard, it is interesting to examine indicators of innovation activity and the commercialization of science as a whole in comparison with other countries.
In a generalized form, Kazakhstan's position in the global technological space is characterized by two groups of indicators: "input" indicators, that is, the level of knowledge intensity, and "output" indicators, namely efficiency and competitiveness indicators.
Kazakhstan's Position in the World in Terms of Knowledge Intensity and Innovation Development
Table 10
Download
| Country | Share of expenditure on research and development in GDP (%) | Number of scientists and engineers engaged in research and development (per 10,000 population) | Current Growth Competitiveness Index — GCI (world ranking) | Share of high-tech products in merchandise exports (%) | Share in global exports of information technology equipment (%) | Labor productivity, thousand US dollars of GDP per employed person |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| USA | 2.69 | 41.0 | 2 | 32 | 13.0 | 73.1 |
| China | 1.00 | 5.5 | 44 | 20 | 7.1 | 7.2 |
| Japan | 2.98 | 51.0 | 11 | 26 | 9.7 | 56.0 |
| India | 1.23 | 1.6 | 56 | 6 | 0.07 | 4.9 |
| Germany | 2.48 | 31.6 | 13 | 18 | 4.8 | 56.0 |
| France | 2.15 | 27.2 | 26 | 23 | 3.4 | 56.5 |
| Great Britain | 1.87 | 26.7 | 15 | 31 | 5.3 | 54.5 |
| Italy | 1.04 | 11.3 | 41 | 10 | 1.1 | 56.5 |
| Russia | 1.00 | 34.8 | 63 | 8 | 0.04 | 18.0 |
| Kazakhstan | 0.26 | 11.5 | 87 | 0 | 0.00 | 5.7 |
| Canada | 1.84 | 29.9 | 16 | 15 | 1.2 | 60.0 |
Note: GCI — Growth Competitiveness Index — reflects the ability of national economies to develop dynamically over the next five years on the basis of new knowledge and technologies.
Source: Dynkin A. The Knowledge Economy in Russia and the World http://fp6.csrs.ru/news/data/dynkin.doc,
Data from the Agency of the Republic of Kazakhstan on Statistics were used for Kazakhstan.
As can be seen from the data presented, the indicators of innovation activity and technology commercialization in Kazakhstan are among the lowest. The absence of high-tech products and information technology equipment in merchandise exports indicates the absence of a domestic innovation system on the international market or its absolute lack of competitiveness. On the other hand, at present, compared with the developed countries of the world, there is a significant gap between obtaining R&D results and their commercialization. The reasons for this situation stem from the general characteristics of the modern Kazakhstani innovation system discussed above.
The biotechnology industry, in which any scientific idea passes through the following stages in its development from an idea to a product:
fundamental science;
applied science;
scaling-up experimental production;
industrial production,
is the most striking manifestation of Kazakhstan's backwardness in the development of its innovation system.
At the same time, on the one hand, biotechnology as such has not been popularized in the Republic, is unknown to a broad range of consumers and businesspeople, and is discussed only in narrow scientific and departmental circles. On the other hand, it is not sufficiently developed, and there are no appropriate developments that would be genuinely in demand in domestic and international markets.
Therefore, in order to ensure the competitiveness of domestic developments in biotechnology, it is extremely important to create conditions for the commercialization of the entire process, from science to product manufacturing.
Foreign specialists attempting to work in Kazakhstan in the field of high-tech business and technology commercialization primarily draw attention to such obstacles as:
a shortage of qualified managers;
corruption and, as a consequence, the lack of transparency of Kazakhstani companies;
a tax regime that does not provide incentives for the development of innovation activity and investment in non-resource sectors of the economy;
the absence of technical infrastructure in the narrow (technological) and broad (unsatisfactory condition of roads, airports, communications and the visa regime) senses of the word.
In this regard, let us examine the experience of developed countries in order to analyze examples of problems hindering the growth of commercialization of scientific and technical developments in biotechnology.
The application of biotechnologies is regulated by numerous national and international rules that create both certain opportunities and difficulties for this industry. Thus, the European Union, seeking to protect itself, intends to establish long-term scientific monitoring of the commercial cultivation of genetically modified agricultural crops over large areas. According to the regulations of the European Union, such monitoring must prove that these crops are harmless both to human health and to the environment. In Germany, testing the safety of genetically modified plants, animals and microorganisms takes between 5 and 6 years.
Difficulties in the widespread use of biotechnologies are also associated with consumer distrust (mainly in European countries) of biotechnological methods in agriculture.
In the case of our country, the population of Kazakhstan is completely uninformed about biotechnology. At the same time, the level of qualification of domestic experts on the harmfulness or harmlessness of biotechnology products is questionable.
In all industrially developed countries, the biological industry operates within the framework of state research programs, with subsequent commercialization of the results by the private sector.
As a result of such a policy, a system of public-private innovation partnerships has emerged in economically developed countries, in which the government and business act as equal partners, mutually complementing each other. By supporting research activities and the education system, which are sources of innovation, the state creates favorable conditions and an environment that stimulates entrepreneurship, while businesses assume all commercial risks associated with operating in the innovative products market. The state derives benefits from tax collection and the resolution of social problems, while businesses obtain their profits.
In our country, a self-regulating business environment for the formation and development of businesses in the biotechnology sector has not emerged. Traditional research institutes and enterprises that exist thanks to state funding are predominantly represented. There is no proper involvement of medium-sized and small businesses.
Biotechnology production facilities are knowledge-intensive enterprises. Without scientific development of new technological methods and new producer strains, enterprises quickly lose their competitiveness.
At present, enterprises have difficulty accessing scientific developments created using public funds and owned by the state. A clearer and more precise legal mechanism is needed for involving such developments in production, up to and including granting innovative companies and industrial enterprises the right to use, free of charge in their production, patented developments created using budget funds and currently not being used.
As the appropriate prerequisites are created, it will be possible to abandon this procedure.
Another difficulty is the practical absence of biotechnology innovation companies in the country. Under the conditions prevailing in Kazakhstan, there is currently no state infrastructure and scientific base in the field of biotechnology capable of providing a foundation for the emergence and development of domestic businesses. A system of state measures aimed at their establishment and support is needed.
In order to establish and develop biotechnology, state development programs have been adopted in practically all countries, including developed countries (Western Europe and Japan), with the exception of the United States, where a biotechnology market genuinely operates. In this regard, all areas of state influence on biotechnology development must be defined in two aspects:
the creation and development of state infrastructure and science on the basis of the National Center for Biotechnology;
the creation of conditions for the development of small and medium-sized businesses, the attraction of private initiative and capital to the biotechnology sector, including through the creation of conditions for access to state, production and financial infrastructure using and implementing advanced scientific developments from domestic and foreign science.
2. Goals and Objectives for the Further Development of the National Center for Biotechnology. The Mission of the National Center for Biotechnology
The goal of the further development of the National Center for Biotechnology is to establish a competitive research institution in the field of biotechnology that meets the highest international standards and operates on the basis of a new method of managing research activities in Kazakhstan, founded on the principles of self-governance and economic self-sufficiency characteristic of the world's leading research institutions.
Based on the foregoing, in order to achieve a breakthrough in biotechnology development in Kazakhstan, the National Center for Biotechnology needs to accomplish the following objectives:
establish new scientific standards and a scientific culture;
develop new samples of biotechnology products and introduce them into production;
promote the development of the bioindustry through the introduction of domestic and advanced foreign developments;
create a competitive environment among scientists through integration into global science;
train a new generation of scientists and highly qualified specialists in the field of biotechnology at a rapid pace;
commercialize the innovation process and conduct scientific and applied research deliberately oriented toward the external biotechnology market;
attract non-governmental funding, both domestic and foreign, through the competitiveness of research and experimental design developments (R&D);
promote the creation of a favorable legislative, investment and infrastructure business environment to stimulate the development of small and medium-sized entrepreneurship in the biotechnology sector;
develop and introduce standards, rules and conditions for authorizing the consumption of biotechnology products of both domestic and foreign manufacture in the Republic of Kazakhstan.
To accomplish these objectives, it is first of all necessary to create conditions for R&D at the level of international standards and attract world-renowned scientists from abroad to develop domestic biotechnology, as well as to conduct systematic research in priority areas.
Mission of the National Center for Biotechnology
The mission of the Center is to develop biotechnology in Kazakhstan — to create knowledge-intensive developments in the field of biotechnology, introduce new developments into domestic industrial production and promote them on the international market.
3. State Policy in the Field of Biotechnology as the Main Mechanism for Implementing the Concept
For the intensive development of biotechnology in Kazakhstan, alongside the import and implementation of advanced foreign achievements (the experience of Japan), it is necessary to develop our own fundamentally new and highly intellectual technologies, taking into account:
the state's readiness to provide ideological, administrative and financial support for innovative transformations;
the republic's preserved scientific and technical potential;
the high level of education of the population, the reformed education system in the Republic, as well as the training of specialists at the world's leading universities through the "Bolashak" program;
the Republic's advantageous geopolitical position;
the multinational culture, interethnic harmony and stability, which make it possible, for example, to carry out interaction and exchange technologies through ethnic ties with historical homelands;
the high investment attractiveness, which makes it possible to select investors willing to open up their technologies for cooperation and support by local specialists and scientists.
The state must take an active position on the establishment and development of domestic biotechnology because "market forces" do not work here. The market on its own will not be able to force investors to leave the currently most profitable raw-material sectors and redirect available capital to sectors with very high risks and much longer payback periods.
The transition to an economy based on high technologies and innovation requires the formation of an integrated system in the country that effectively transforms new knowledge into new technologies, products and services that find actual consumers in national and global markets. In this regard, the main objectives of scientific and technical policy are the development of research aimed at improving the quality of life, the development of knowledge-intensive, resource-saving and environmentally friendly industries focused on exporting high-tech products, the gradual replacement of the raw-material orientation of the economy with a technological orientation, and the replacement of the technological orientation with an intellectual and information-based orientation, as well as the training of highly qualified specialists for these purposes.
The following tasks need to be addressed in order to achieve their implementation:
- improving the system for organizing science and scientific and technical activities, the regulatory legal and methodological framework, including in the areas of financing research and development (R&D), their competitive selection and practical implementation of results, and the protection of intellectual property rights;
- optimizing fundamental research;
- giving priority to directing applied research towards the scientific and technological provision of the needs of the basic sectors of the economy;
- creating favorable conditions for the establishment of new knowledge-intensive industries and the development of innovative activities, contributing to the transition to a unified research and production cycle of “research – development – industrial освоение”;
- developing new import-substituting (export-oriented) technologies for the production of knowledge-intensive products, further strengthening (reconstruction, technical re-equipment) and developing the country's own experimental and pilot production facilities and production and technical infrastructure;
- restructuring and privatizing certain facilities in the scientific and technical sector while preserving their field of activity;
- attracting investment for the establishment and development of knowledge-intensive industries, and introducing resource-saving and environmentally friendly technologies;
- ensuring the sustainable development of small and medium-sized enterprises, and establishing and developing elements of market infrastructure in the field of science and scientific and technical activities;
- developing an effective mechanism for integrating research institutes, sectoral scientific and technical centers and higher education institutions, as well as the processes of education and scientific activity;
- training personnel, including highly qualified specialists, in priority areas, thereby ensuring the preservation and development of the country's intellectual potential;
- involving the country's scientific community in selecting and adapting advanced foreign technologies to domestic conditions and their industrial implementation;
- accelerating the integration of Kazakhstani science into the global scientific and technological space.
There are numerous mechanisms through which the state in developed countries around the world participates in creating a favorable investment climate and facilitates the commercialization of research results. In general terms, the instruments used can be divided into several major groups:
- direct financial participation by the state in the form of financing specific projects (for example, financing a program for the development of the National Center for Biotechnology or participation in venture financing) or organizations (for example, small research and production companies);
- supporting links between the public and private sectors in the research and development field (public-private partnership);
- financing the establishment of elements of production and technological infrastructure (research centers, technology parks, incubators, technology promotion offices);
- creating substantial incentives for private capital by sharing risks, reducing the tax burden and eliminating various types of barriers.
Within the framework of the Industrial and Innovation Development Strategy, the following conditions need to be implemented in Kazakhstan:
1) The main condition for creating modern biotechnologies in Kazakhstan is the development of a modern model of science in the field of biotechnology, with the National Center for Biotechnology serving as its flagship. Biotechnology is a knowledge-intensive industry, meaning that its development is impossible without close cooperation between research centers and industry. This entails the practical implementation of an integrated approach to establishing both the research system itself and mechanisms for interaction between science, education, small innovative businesses, large industrial corporations and relevant financial institutions, as well as implementing the chain of fundamental science – applied science – experimental production – industrial production;
2) An important role is assigned to the small innovative entrepreneurship (SIE) sector, which plays a leading role in testing and mastering the latest and riskiest biotechnologies. Throughout the world, the SIE sector is the driving force behind the innovative development of high-tech industrial sectors.
For the rapid development of the SIE sector, it is necessary to establish modern innovation infrastructure, including its subsystems.
The application of biotechnological products generally requires changes to the technologies used in the relevant production processes. The state should assist enterprises wishing to apply modern technologies based on the use of biotechnological products in carrying out the necessary transformations.
At the present stage, in our opinion, it is also advisable to support enterprises purchasing domestically produced biotechnological products. Such a procedure, for example, could apply to agricultural enterprises purchasing domestically produced mineral fertilizers and plant protection products.
Customs policy issues also belong to this category. Tariff policy needs to be tightened. Tariffs should be used to counteract the importation of products that domestic enterprises are capable of successfully producing;
3) The financial infrastructure of the innovation system (IS) should ensure effective access for innovation entities to public and private financial resources. For example, the system of scientific, technical and innovation funds is an integral part of the financial infrastructure of developed countries around the world. The effectiveness of these funds is determined by the fact that they simultaneously ensure the competitive selection of the most promising projects, their targeted financing and monitoring of the use of the funds received. The country's biotechnology enterprises currently require significant investment to replace obsolete and worn-out fixed assets and acquire modern producer strains and technologies.
Enterprises do not have the necessary resources. The use of loans, the interest rates on which are 2–3 times higher than those abroad, places enterprises at a deliberately disadvantageous position compared with foreign competitors.
It appears that the state should clarify its tax policy with regard to high-tech enterprises, particularly biotechnology enterprises, by reducing the tax burden and providing tax incentives.
In the operation of Kazakhstani development institutions, their accessibility to small business entities must be ensured;
4) The state funds operating in Kazakhstan that support innovation activities and the commercialization of technologies can be incorporated more effectively into the process of establishing the IS by improving the regulatory and legal conditions governing their operations.
First and foremost, clear procedures must be developed for assigning and transferring rights to intellectual property created using funds provided by these funds, as well as for the possibility of valuing and pledging such intangible assets as intellectual property rights and others;
The experience of Kazakhstani development institutions operating in the regions can serve as a catalyst for launching initiatives at the local level and contribute to attracting regional budget funds to the biotechnology sector. Facilities may be financed on a shared basis, with the participation of local authorities, other funds and private investment. This will make it possible to concentrate sufficient funds for testing experimental production and rapidly launching industrial production in the biotechnology sector, primarily in regions with high innovation potential;
Venture capital funds are an important financial institution in the field of commercialization. At present, venture capital funds have not achieved sufficient development in Kazakhstan. The reasons are partly attributable to the absence of strong incentives for investing in high-risk projects in circumstances where investing funds in raw materials industries is considerably more reliable (therefore, tax payment incentives, the gratuitous allocation of land, and so forth, may serve as the basis for their establishment, or the attraction of foreign capital may be considered).
In connection with the emergence of new types of funds (including venture capital funds), as well as for the purpose of harmonization with budgetary and tax legislation, amendments need to be made to the Laws of the Republic of Kazakhstan “On Science”, “On Innovation Activity” and other laws;
7) the development of training programs for personnel for high-tech businesses should be carried out in the following areas:
firstly, it is advisable to implement training programs on a shared-financing basis, provided that business entities contribute co-financing;
secondly, educational programs, training courses and seminars should preferably be oriented towards two target groups of recipients: scientists and administrators of institutions, as well as entrepreneurs operating in the small innovative business sector, on the one hand, and representatives of executive authorities, on the other;
8) it is necessary to develop a state program entitled “Development of Biotechnology in Kazakhstan for 2008–2012”. The main idea of the Program is to develop a system of measures aimed at eliminating negative trends and creating optimal conditions for the development of fundamental and applied biotechnology.
Within the framework of this program, specific measures should be envisaged to address tasks that are interrelated and coordinated in terms of timing, resources and implementing parties, including research and development, material and technical, personnel, information, regulatory, legal and economic support.
§ 1. Determining the Most Effective Management Model for Scientific Organizations and Research in the Field of Biotechnology in Kazakhstan
The experience of the most developed countries demonstrates the high efficiency of concentrating scientific research in specialized innovation centers. At the initial stages of the development of innovation centers, both targeted state funding in accordance with state programs for the development of the innovation sector and financing through grants from international organizations and corporations are envisaged. Subsequently (after 7–10 years), the centers achieve self-sufficiency and self-financing through the commercialization and implementation of scientific developments.
Financing of Biotechnology Centers Worldwide
Table 11
Download
| Country | Number of centers | Annual funding per center (USD million) | Maximum funding period (years) | Start of the state program |
|---|---|---|---|---|
| Taiwan | 2 | 2.3 | Indefinite | 1997 |
| Hungary | 6 | - | 1999 | |
| Netherlands | 6 | 1.3 | 10 | 1998 |
| Poland | 9 | 0.5 | 3 | 1999 |
| Ireland | 10 | 2.0 | 7 | 1999 |
| Australia | 11 | 0.9 | 9 | 2000 |
| Canada | 15 | 3.0 | 14 | 1988 |
| Austria | 16 | 0.8 | 10 | 1993 |
| Switzerland | 18 | 12.0 | 10 | 1992 |
| Japan | 20 | 4.3 | 10 | 1993 |
| Denmark | 25 | 1.2 | 10 | 1993 |
| Finland | 26 | 1.5 | 10 | 1995 |
| South Korea | 61 | 2.3 | 9 | 1990 |
Despite the lag in the development of Kazakhstani science in the field of biotechnology, a number of favorable factors have emerged in the republic that may facilitate the rapid integration of domestic science into the international innovation system. These include:
the openness of the national economy and its integration, to one degree or another, into the global economy;
the legislative recognition of the right to private property, including property rights to the results of intellectual activity;
equality of economic entities, including the state, in economic activity;
commitment to market economy standards and the legislative provision of a competitive environment, which constantly orients producers towards consumer interests and stimulates the continuous creation of innovations;
high overall economic growth rates, high investment attractiveness and a favorable social and political situation in the country.
In view of the above, the most effective model for organizing research activities in the Republic of Kazakhstan would be the establishment of specialized divisions within the National Center for Biotechnology that would conduct fundamental and applied research and experimental design development, followed by the creation of prototypes, their testing and refinement to the “commercial product” stage, and further implementation of the entire cycle. On the one hand, research topics would be determined by the needs of the global market; on the other hand, fundamental research would make it possible to forecast future development paths and societal needs, thereby ensuring that applied research developments will be in demand in the future. The result of the activities of such divisions would be products ready for mass production in accordance with demand.
Alongside the National Center for Biotechnology, which receives state funding, small innovative businesses will naturally emerge and develop. In general, the organizational structures of market-based innovation systems are characterized by a combination of large integrated leading companies operating in national and global economies with numerous companies in the SIE sector, which carry out pioneering, high-risk innovation and technological activities, including through the innovation infrastructure of the leading company.
In this regard, it is necessary once again to emphasize the importance of a well-considered state policy aimed at creating a favorable environment that stimulates the widespread introduction of innovations in biotechnology.
§ 2. Introduction of International Standards into the Education System and Development of Human Resources
The implementation of biotechnology projects requires the involvement of highly professional management personnel.
In Kazakhstan, education in the field of technology management is a developing area. The shortage of qualified personnel both for structures directly engaged in technology transfer and for specialized divisions of research institutes and universities is widely recognized. Modern specializations in technology management have been introduced at many universities; however, the quality of specialist training does not meet international standards.
At a minimum, training programs should be based on the following principles:
extensive analysis of specific examples of the establishment and development of Kazakhstani and foreign technology companies;
practical training based on the management of specific projects;
participation of Kazakhstani and foreign practitioners specializing in technology commercialization in teaching and advising trainees.
At the same time, Kazakhstan has a wide range of qualified educational programs covering such areas as strategy, marketing, finance and personnel management, that is, the application of interdisciplinary analysis. In accordance with international practice, training methods also involve engaging and developing the leadership qualities of trainees.
Training in the field of technology management is financed either through the state budget or on a mixed basis (course participants pay for their training). This distinguishes the situation in Kazakhstan from that in developed countries around the world. For example, in the United States, the United Kingdom and Israel, the state does not assume the costs of training technology managers. Such personnel are usually trained at private business schools or within structures affiliated with incubators. Given that the entire innovation system is a new phenomenon in our country, measures of state support are necessary.
Training personnel for high-tech businesses is not simply a matter of introducing new courses in addition to existing ones. It involves changing the conceptual approach to personnel training.
Firstly, high-quality business education is not intended to be mass education; therefore, the structure of courses and educational standards in this field should be similar to those of elite schools and faculties. Kazakhstan has experience in training qualified personnel for the natural sciences, which can be used in developing a business education system.
Secondly, technology managers must be capable of continuous learning, possess flexibility, be able to anticipate future developments, constantly adjust strategies and seek alternatives. Therefore, it is important that students undertake internships at different companies from the very beginning of their training and solve not only hypothetical but also real-world problems. However, there is also a problem here: learning through practical experience presupposes extensive experience, which is currently very limited in Kazakhstan. Consequently, there are also few qualified instructors who simultaneously possess experience in successful technology management.
Thirdly, there should be at least co-financing of such educational programs by businesses. For example, businesses could provide targeted grants. Such a scheme is already in operation, but on a small scale. The development of business-funded training is hindered by the constant movement of personnel between business entities, often competitors. The same problem exists with personnel certified under the programs of global brands.
In international practice, scientific groups at Centers are headed by scientists who have established themselves in the global scientific community and possess organizational experience. Creative teams are formed around them, providing a favorable environment for improving the overall level of the team. Universities are often involved in the activities of the Centers, and students and postgraduate students gain practical experience in science and pilot production.
In its activities, the Center plans to be guided by advanced methods of personnel selection, recruitment and training, including the development and implementation of a new training methodology based on the “training of trainers” principle. The “training of trainers” method combines “theoretical” courses with the practical consolidation of acquired knowledge. By providing trainees with independence, the Center effectively trains new managers who, in turn, will pass on their acquired experience and knowledge to subsequent generations. As a result, the Center will become a kind of institution where new personnel, including employees of cooperating organizations, will be trained and gain practical experience working in accordance with international standards. Subsequently, they will be able to occupy management positions in other research institutions and laboratories, particularly those affiliated with universities.
§ 3. Issues Concerning the Protection of Intellectual Property Rights
Since February 16, 1993, the Republic of Kazakhstan has been a party to four major international conventions on the protection of industrial property: the Paris Convention for the Protection of Industrial Property of March 20, 1883; the Madrid Agreement Concerning the International Registration of Marks of April 14, 1891; the Convention Establishing the World Intellectual Property Organization, signed in Stockholm on June 14, 1967; and the Patent Cooperation Treaty (PCT), signed in Washington on June 19, 1970. Since November 5, 1995, the Eurasian Patent Convention, signed by the heads of government in Moscow on September 9, 1994, has also applied to the territory of our country.
The regulation of the protection of biotechnological objects and genetic resources at the international level has been particularly intensive over the past two decades and has been reflected in a number of documents.
An important international document for addressing the issue of biodiversity on Earth and regulating the use of genetic resources is the Convention on Biological Diversity (Rio de Janeiro, June 5, 1992), approved by the Republic of Kazakhstan pursuant to Resolution No. 918 of the Cabinet of Ministers of the Republic of Kazakhstan dated August 19, 1994.
Articles 15, 16, and 19 of the Convention set forth the provision that “in recognition of the sovereign rights of States over their natural resources, the authority to determine access to genetic resources rests with national governments and is subject to national legislation” and that “access to genetic resources, where granted, shall be on mutually agreed terms and subject to prior informed consent”.
Intellectual property protection systems (through patents, plant breeders' rights, copyrights, trade secrets and other mechanisms) provide holders of the relevant rights with the opportunity to exclusively use the results of inventions for at least a certain period of time. In most cases, the holders of intellectual property rights are industrial corporations, research and educational institutions, although they may also be private individuals. When determining patentability, compliance with the criteria of novelty, inventive step and industrial applicability is assessed.
International trade in innovation systems (IS) is an important factor in global development. In the absence of reliable intellectual property rights, the incentive to invent is lost, while countries that do not ensure the protection of such rights create incentives to copy other people's inventions instead of developing their own.
In connection with Kazakhstan's preparations for accession to the World Trade Organization (WTO), one of the important issues is bringing national intellectual property legislation into compliance with the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
Efforts to extend the provisions of the TRIPS Agreement to the patenting of living organisms are being intensified. Biotechnological inventions belong to the category of inventions recognized worldwide in accordance with TRIPS standards; consequently, the legal protection of biotechnological inventions does not require the adoption of a separate legislative act and is regulated by national patent laws.
The harmonization of patent protection for biotechnological innovations is still hindered by the fact that WTO documents do not mention the participation of countries of origin of genetic resources in the possible benefits derived from their use. Work on this proposal has begun through WIPO (the World Intellectual Property Organization). Efforts to identify ways of complying with the principles of the Convention are also being undertaken by the International Union for the Protection of New Varieties of Plants (UPOV).
On April 24, 2002, the Republic of Kazakhstan acceded to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (hereinafter referred to as the Budapest Treaty).
Resolution No. 850 of the Government of the Republic of Kazakhstan dated July 30, 2002, “On the Republican Collection of Microorganisms”, establishes, in accordance with the Treaty, the task of nominating the collection as an International Depositary Authority (IDA). Obtaining IDA status for the national collection is important for foreign patenting, since an international application requires the deposit to be made specifically with a collection that has IDA status.
European countries are also actively implementing measures to improve the legal protection of biological objects, including those obtained through genetic engineering. In 1998, the Council of the European Union and the European Parliament adopted EU Directive No. 98/44/EC on the legal protection of biotechnological inventions (hereinafter referred to as the “Directive”), which entered into force on July 30, 1998. The main political objectives of the EU Directive are, firstly, to strengthen the protection of biotechnological inventions in order to preserve and encourage investment in this field and, secondly, to harmonize protection in order to prevent differing approaches in the practices and case law of national courts and patent offices that negatively affect trade within the European Union.
The amendments made last year to the Rules for Drafting, Filing and Examining Eurasian Applications at the Eurasian Patent Office, following the example of the European Patent Office, are of great importance for legal protection in the Eurasian region.
It should be noted that, in general, the current regulatory legal framework in the Republic of Kazakhstan in the field of intellectual property complies with the main provisions of the international treaties and conventions to which the country is a party.
Further development concerns the harmonization and alignment of national legislation in the field of intellectual property rights protection with the TRIPS Agreement. In order to integrate into the global economy, it is necessary to strengthen the attention of all state and judicial authorities to the protection of intellectual property, make this one of the most important areas of the Republic's state and economic policy, and, for these purposes, promote the enhanced role of the Committee for the Protection of Intellectual Property Rights of the Ministry of Justice of the Republic of Kazakhstan as the authorized body in this field in establishing and operating the intellectual property protection system in the Republic of Kazakhstan.
Higher education institutions and research institutes play a significant role in patenting in the field of biotechnology in the Republic of Kazakhstan, and their role in the development of biotechnology should increase.
The absence of an appropriate system for recording and monitoring research projects implemented through international scientific and technical cooperation leads to the uncontrolled export of Kazakhstan's intellectual property abroad without adequate financial compensation, particularly intellectual property created using state budget funds. In this regard, it is important to consider issues concerning the exercise of the state's rights and the accounting of the balance of interests in relation to intellectual property objects created using state budget funds.
Research organizations should move from simply administering intellectual property portfolios to managing them strategically. Intellectual property management should become one of the objectives of state organizations, alongside education and research.
It is necessary to emphasize the importance and priority of patent and market research in R&D. This is one of the main information and analytical components of marketing research. Access to information, including patent databases, must be ensured for the scientific community.
In addition, support for research and development projects by young researchers, as well as patent law and licensing activities as an integral part of research work, should be provided for in the innovation sector.
Forecasting the directions of scientific and technological development, selecting solutions that will make it possible to achieve the most effective results in each sector of the economy, and determining the priorities for further scientific and technological development.
Placing at the forefront the need to ensure that participants in the innovation process are maximally interested in achieving the implementation of R&D projects that have produced technical solutions offering the highest efficiency compared with similar objects, that is, solutions supported at the R&D stage and granted patent protection. The stimulation of inventive and innovative activities should be linked to the effectiveness of the use of the results of such activities rather than to the process itself.
Universities should train people who are not only familiar with the fundamentals of innovation studies but who are also committed advocates of the innovation economy and the knowledge economy. Scientists and future scientists should receive universal training in the fundamentals of intellectual property.
§ 4. Development of the Regulatory Legal Framework
At present, certain elements of the state support system for innovation-driven industrial development have been established in the Republic (state funds and other development institutions, technology parks), but they operate without being interconnected with one another or with other sectors of the economy, such as industry and education. At the same time, foreign experience was borrowed by transferring individual elements of comprehensive economic mechanisms, which therefore failed to produce the expected results. As a result, despite the positive experience of a number of initiatives, no breakthrough has been achieved in the field of innovative economic development. The main problem remains the absence of effective economic mechanisms that stimulate both investment in the innovation sector and the creation of innovations, as well as their commercialization.
Under our conditions, there is only one way to create and develop an innovation economy: the state must pursue a responsible and consistent scientific and technological policy that ensures an adequate level of budget financing for scientific research (combined with an effective mechanism for allocating such funding) and creates favorable conditions for knowledge-intensive businesses. Examples of successful implementation of such a policy, pursued over several decades, include Japan and South Korea, which started from a much lower level of scientific development than Kazakhstan currently has. China is now following the same path. In these countries, as well as in the United States and the European Union, applied science exists in close association with fundamental science. Fundamental science serves as a “nourishing environment” for applied science and higher education, while the state stimulates the transfer of ideas and people into high-tech businesses.
Today, there are almost no differences between fundamental and applied science, particularly in certain priority sectors. Finland, which has risen to the ranks of global post-industrial leaders over the past 15 years (as have Sweden and Switzerland), has never had traditions or significant achievements in fundamental science.
The state has still not adopted generally accepted international standards for the ownership, use and management of intellectual property. One of the most important problems associated with the use of intellectual property is the shadow export of technologies.
Many companies engaged in the development of new technologies prefer foreign patenting and licensing their technologies to foreign companies. As a rule, foreign patenting takes place in violation of the patent legislation of the Republic of Kazakhstan.
As a result of foreign patenting, the Kazakhstani economy loses most of the potential profits received by countries that have effective economic and legal mechanisms for commercializing new technologies.
The lack of demand for intellectual property results in a mass brain drain.
Currently, innovation activity in Kazakhstan is regulated by the Law of the Republic of Kazakhstan “On Innovation Activity”, which defines the fundamental principles, areas and forms of implementation of state innovation policy, as well as by other subordinate regulatory legal acts implementing the provisions of this Law. Relations in the field of intellectual property arising from the creation of intellectual property, the legal protection and use of intellectual property objects are reflected in the Laws of the Republic of Kazakhstan “On Copyright and Related Rights” and “Patent Law of the Republic of Kazakhstan”. The rights and obligations of entities in the scientific and scientific and technical sectors are regulated by the Law of the Republic of Kazakhstan “On Science”.
Kazakhstan's patent legislation lacks developed mechanisms for its implementation and judicial practice concerning the consideration of cases involving the transfer of rights. Violations of intellectual property rights are caused by shortcomings in patenting practices, which do not guarantee patent holders the protection of their exclusive rights. This occurs for several reasons. There are three types of patenting: the patenting of ideas, research developments and experimental design developments. At each stage, an already patented development may be taken as a basis, slightly modified and patented as one's own. If an idea is protected by a patent but has not been implemented, there is a high probability that it will be used by a company with sufficient scientific and financial resources, patented as a research development in Kazakhstan and other countries, and embodied in a specific product. Therefore, authors of innovations in the Republic of Kazakhstan resort to patenting only when an innovation is ready for mass production or is being sold abroad. In addition, patent registration requires a considerable amount of time. A company that obtains “insider” information patents it abroad, which automatically deprives its true owner of many rights and opportunities.
There is still no clear policy regarding the ownership of rights. The author of an innovation has no incentive to develop their ideas at a state-owned enterprise. Promising ideas move into the private sector. As a result, unfair competition arises between employees and employers, and between contractors under civil law agreements and customers. For the state, this means lost potential revenue.
Current legislation does not specifically distinguish objects created using public funding. Consequently, the same legal provisions apply to them as to intellectual property objects created in the performance of official assignments.
The state should strengthen sanctions for violations of intellectual property rights. A reasonable pricing policy is also necessary. In order to attract potential buyers of pirated products, the rights holder should reduce the price of the intellectual product.
The conditions for an organization to acquire and use rights to the results of scientific and technological activities should be reflected in an agreement with the relevant republican executive authorities, academies of sciences having state status, and state scientific funds acting as the chief administrators of the aforementioned budget funds.
These provisions are particularly important for the operation of state funds supporting scientific research. It is necessary to develop Kazakhstani equivalents of the Bayh–Dole Act and other legislative acts aimed at improving the regulatory legal framework governing the protection, enforcement and use of the results of intellectual activity created using funds from the republican budget, based on the principle of assigning rights to such results to the implementing organizations while simultaneously establishing conditions for their commercialization.
For the successful introduction in Kazakhstan of economic mechanisms in the field of innovative economic development, particularly in the sphere of scientific and scientific and technical activities, new laws and other regulatory legal acts are required, and existing legislation must be amended.
For example, the country still has no law regulating the circulation of microbiological resources. The regulatory framework in this area needs to be developed.
It is necessary to expand the areas of state financing of scientific and innovation activities, create conditions for development institutions willing to invest in technological innovations, and legislatively establish the priority of biotechnology development.
The state should also create substantial incentives for private capital by sharing risks, reducing the tax burden, eliminating various types of barriers and investing in infrastructure. At present, tax legislation provides indirect regulation (tax, customs and depreciation-related) of high-tech sectors, whereas such regulation should become incentive-based.
In particular, for the purpose of commercializing scientific developments, it is necessary to introduce additional criteria for competitive selection in relation to initiative-based and high-risk research:
the degree of completion of the planned research in terms of the possibility of its implementation and obtaining a commercial effect from its realization;
the existence and degree of development of marketing studies concerning the further commercialization of research results.
It is necessary to create conditions for the formation of a new generation of the national scientific school. Young people's interest in natural science and technical universities, which has increased somewhat over the past one or two years, must be supported and developed. To this end, incentives for young specialists to enter the field of scientific and scientific-technical activities must be enshrined in legislation, the convergence of science and education must be accelerated, and the potential of the Kazakh scientific diaspora working abroad must be utilized. Resolving the personnel problem will provide a qualitatively new impetus to the process of reviving domestic fundamental science and developing applied science.
An innovation culture, modern management in science, and an orientation towards public needs and demand must be established at universities and scientific organizations. The legislative framework must guarantee the effective use of budgetary funds, introduce new financing mechanisms and a system for organizing scientific activities with developed production, technological and information infrastructure, and simplify licensing, certification and patenting procedures.
The objective of developing the legislative framework in Kazakhstan should be to ensure:
the functioning of a new innovation system characteristic of market economies;
the organization of the private sector of industry and services ("in-house research"), small innovative enterprises, and numerous non-governmental non-profit scientific, analytical, consulting and other centers;
recognition of the biotechnology sector as a major national priority;
priority financial support for the development of biotechnology, bioengineering and biosafety;
the creation of scientific and industrial infrastructure that meets international standards;
the recruitment of young talented researchers to implement the national programme on biotechnology, bioengineering and biosafety, and the creation of optimal production, housing and financial conditions for them;
the provision of continuous and objective information to the entire population of the country regarding the content and results of research in biotechnology, bioengineering and biosafety;
the improvement of the legislative and other regulatory framework in the fields of biotechnology, bioengineering and biosafety;
the establishment in the country of a special Republican Council on Biotechnology, Bioengineering and Biosafety.
The implementation of joint international projects will enable our country to overcome its technological lag and join the ranks of the world's highly developed countries in this field of science and production.
4. Development of the National Center for Biotechnology in accordance with the new model of science and innovation management
In order to establish the National Center for Biotechnology, taking into account the state's position on the breakthrough development of biotechnology, the use of specialized research institutes and higher education institutions, as well as the creation of a bioindustry, the following measures are necessary:
a state budget programme for the development of the National Center for Biotechnology;
state investment in the Center's production and technological infrastructure;
corporatization of the National Center for Biotechnology, which предусматривает the establishment of a joint-stock company with 100% state participation, since international best practices in the development of the biotechnology science sector demonstrate that the consistent development of biotechnology is impossible without the direct participation of the state;
the establishment of an autonomous scientific structure within the National Center for Biotechnology, independent of bureaucratic interference and offering maximum flexibility for the implementation of R&D projects, consisting of groups of scientists sharing common scientific and research approaches; the head of each group shall be a scientist recognized in the international scientific community and possessing organizational management experience;
the creation of a favorable tax and investment regime, and the introduction of amendments and additions to the Laws of the Republic of Kazakhstan "On Innovation Activity", "On Science", "On Education", "On Copyright and Related Rights", and the Code of the Republic of Kazakhstan "On Taxes and Other Obligatory Payments to the Budget" (the Tax Code);
the development of the patenting system;
the establishment of alliances with leading international corporations and companies in the field of biotechnology.
The strategy of the National Center for Biotechnology's activities in the market of knowledge-intensive industries should be to create conditions for conducting R&D in accordance with the criteria applied by the world's leading scientific centers:
commitment to scientific and academic ethics and tolerance;
the creation of conditions for the free exchange of information;
the economic independence of the heads of research groups;
the unity of scientific and educational processes and the targeted training of national scientific personnel in accordance with international standards.
The 2001 report prepared by BCD on the world's best innovation centers identified the key criteria for their success. There were five such criteria:
proximity to research institutes;
the availability of corporate role models for disseminating experience;
entrepreneurial intelligence;
the ability to attract personnel;
access to venture capital.
As follows from this list, three of the five indicators relate to the quality of management and personnel training. Therefore, attracting leading scientists of international renown to serve as heads of research groups is of great importance.
The competitiveness of the National Center for Biotechnology will be determined by:
personnel – highly qualified heads of research groups with extensive experience working at leading foreign universities, medical research centers, biotechnology companies and national laboratories;
material and technical resources – a scientific and experimental base at the level of leading Western laboratories (establishment of laboratories compliant with GLP standards, modern equipment and materials);
self-financing – at present, the National Center for Biotechnology of the Republic of Kazakhstan is a subject of the Law of the Republic of Kazakhstan "On Science", operates on equal terms with all organizations in the field of science and receives program-targeted funding through participation in competitive selection procedures.
Transition to self-financing within 5-7 years through international grants and the commercialization of scientific developments. The transition to self-financing is a guarantee of research competitiveness.
Positioning of the National Center for Biotechnology in the economy and in the market of knowledge-intensive industries of the Republic of Kazakhstan
The priority measures of the NCB in innovation activities in the field of science and scientific and technical activities should focus on:
the examination of existing scientific developments, the maximum dissemination of completed high-quality developments, and their commercialization in domestic and international markets;
the acquisition of foreign patents and licenses necessary for the development of advanced knowledge-intensive technologies in the Republic; their adaptation to local conditions;
conducting research aimed at improving the acquired technologies in the future or creating new, more advanced technologies on their basis;
the development of human resources and the recruitment of internationally recognized scientists to establish a national scientific school;
the development of modern scientific and experimental infrastructure, laboratories and research facilities;
the continuous establishment and support of small-scale production facilities that implement innovations using existing scientific, technological and production capacities, primarily at the level of incremental technologies.
Following this, it is essential to conduct the Center's own prospective research aimed at creating new knowledge-intensive technologies and industries. Fundamental science should be concentrated at the NCB's head office, while experimental and industrial production should be carried out in its branches.
The branches should assume the functions of preparing technologies for implementation or export. Their infrastructure should be accessible to small and medium-sized businesses and include appropriate administrative, patent, engineering and design, marketing and analytical support services for developments. The main task of the NCB should be the commercialization of scientific developments and the promotion of products to the market through the involvement of private initiative and public-private partnerships.
Areas of biotechnology development that are relevant to the Republic of Kazakhstan and should become the subject of research by the NCB
In medicine:
the development and production of new biologically active substances and medicines based on natural compounds;
the development of next-generation recombinant vaccines against various infectious diseases. Unlike many vaccines currently in use, they are non-toxic and have no side effects;
the development of treatment methods based on fundamentally new mechanisms of action (gene therapy, antisense RNA, and the like);
the study of heredity and the genetic predisposition of the human body to various diseases. The creation of genetic databases and genetic passports of the population is of great importance, given the global increase in oncological, infectious and hereditary diseases;
the development of methods for early diagnosis of diseases.
In the enzyme industry:
the production of enzymes for the manufacture of detergents;
the production of enzymes for the textile industry;
the production of enzymes for the processing of hydrocarbon raw materials;
the production of enzymes for the dairy industry;
the production of other enzymes.
In the agro-industrial complex:
the development of new varieties of plants and domestic animals with improved characteristics: increased biomass growth, resistance to diseases and stress, including adaptation to arid and sharply continental climatic conditions, saline soils, and so forth;
the development of new environmentally friendly methods of combating microorganisms, plants and animal species harmful to agriculture.
In the extractive industry:
the introduction of biotechnological methods into the extraction and processing of mineral resources, oil and gas.
In ecology and the protection of the environment from pollution and waste resulting from human activities in nature through biological methods (bioremediation), including:
the elimination of the consequences of oil pollution both on land and in the hydrosphere;
the neutralization of radioactive radiation and the toxicity of industrial waste in waste dumps and water bodies, agricultural lands of the Semipalatinsk Test Site, and territories affected by rocket and space activities;
the purification of air from smog in large cities (the city of Almaty) and industrial zones, from vehicle exhaust emissions and emissions arising from the flaring of associated gas during oil production.
In biosafety:
the development and implementation of standards, rules and conditions governing the authorization of biotechnology products for consumption;
the determination of criteria, indicators and methods for assessing biological safety, genetically modified organisms and products derived from them;
the organization of a system of state control and regulation of genetic engineering activities.
5. Stages and expected results of the implementation of the Concept
§ 1. Stages of implementation of the Concept
Stage 1 – 2006. Establishment of the National Center for Biotechnology on the basis of a new model for organizing science and innovation activities through corporatization with 100% state participation. Development of a legislative framework that stimulates the development and introduction of high technologies and ensures the investment attractiveness of biotechnology development in Kazakhstan.
Stage 2 – 2006-2008. Within the framework of the Concept, beginning in 2006, the scientific and technical programme "Development of Modern Technologies for the Formation of a Biotechnology Cluster in the Republic of Kazakhstan for 2006-2008" (hereinafter referred to as the Programme) will be implemented.
Another component of the implementation of the Concept for 2006-2008 is the construction of new infrastructure for the National Center for Biotechnology of the Republic of Kazakhstan on the left bank of the city of Astana.
§ 2. Expected results of the implementation of the Concept
As a result of the implementation of the Concept, the National Center for Biotechnology (NCB) will become a competitive research institution in the field of biotechnology, meeting the highest international standards.
A domestic bioindustry will be established in Kazakhstan, with the NCB as its flagship. Domestic knowledge-intensive products of the biotechnology cluster, meeting universally recognized international standards, will be duly represented on the global market.
All the prerequisites will be created for transforming the NCB into a large industrial corporation with strong in-house research.
The NCB will operate according to a clearly established chain: fundamental science – applied science – experimental production – implementation. Research enterprises will be established in the NCB's branches, where the NCB's developments will be implemented, and industrial production facilities will be organized jointly with private businesses, with the involvement of domestic development institutions and foreign capital.
Kazakhstani science will be integrated into the global scientific community, a new generation of scientists and highly qualified specialists will be trained, and a domestic school of biotechnology will be established.
A clear system of state regulation and control over the safe use of biotechnology products will operate in Kazakhstan.
Following the example of biotechnology, the innovation process in other sectors will be commercialized. A favorable legislative, investment and infrastructure-based business environment will be established to stimulate the development of entrepreneurship in the fields of innovative and high-tech business.
Kazakhstan's economy will be oriented towards the deep processing of mineral resources and the development of an advanced industry of high, knowledge-intensive technologies. The economy will achieve a zone of sustainable growth and efficiency in the field of biotechnology.
The main result of the implementation of the Concept will be the provision of domestic biotechnology products to the population. The following problems will also be addressed:
the development and mass production of socially significant domestic biotechnology products;
the retention of personnel and the resolution of employment problems in a number of regions of the Republic of Kazakhstan, as well as in areas of scientific and technological development specializing in biological and biotechnological fields;
the resolution of biological and environmental safety issues;
the creation of a promising, stable, import-substituting market for products and services in high demand (food, medicines, diagnostic kits).
The social impact of implementing the Concept may be significant if the planned indicators are achieved (the involvement of domestic personnel in a high-income, knowledge-intensive process, the development of qualified personnel, ensuring biosafety, and so forth). High economic efficiency is projected from the implementation of the Concept due to the profitability of biotechnological production facilities and the entry of domestic products into the international market.
6. Required funding amounts and sources
The feasibility study for the investment project "Development of the National Center for Biotechnology of the Republic of Kazakhstan" was prepared in 2005 using funds from the republican budget in the amount of 58.3 million tenge.
Within the framework of the Concept, beginning in 2006, the scientific and technical programme "Development of Modern Technologies for the Formation of a Biotechnology Cluster in the Republic of Kazakhstan for 2006-2008" will be implemented. The financial resources allocated in the republican budget for the implementation of the Programme amount to 1,433.00* million tenge, including: in 2006 – 450.0 million tenge, in 2007 – 477.0* million tenge, and in 2008 – 506.0* million tenge. (Decision No. 14 of the Republican Budget Commission dated July 29, 2005, Resolution of the Government of the Republic of Kazakhstan No. 884 dated August 26, 2005, "On the Medium-Term Plan for the Socio-Economic Development of the Republic of Kazakhstan for 2006-2008").
Another component of the implementation of the Concept is the construction of new infrastructure for the National Center for Biotechnology of the Republic of Kazakhstan on the left bank of the city of Astana. The estimated expenditure of republican budget funds for the construction of the Center amounts to 8,495.34* million tenge, including: in 2006 – 600.00 million tenge, in 2007 – 4,886.81* million tenge, and in 2008 – 3,008.53* million tenge. (Decision No. 14 of the Republican Budget Commission dated July 29, 2005, Resolution of the Government of the Republic of Kazakhstan No. 884 dated August 26, 2005, "On the Medium-Term Plan for the Socio-Economic Development of the Republic of Kazakhstan for 2006-2008").
___________________________
\* The amounts of funds from the republican budget for 2007-2008 shall be subject to clarification and submission to the Republican Budget Commission for consideration in accordance with the Law of the Republic of Kazakhstan "On the Republican Budget" for the relevant financial year.
| | Approved by Resolution No. 363 of the Government of the Republic of Kazakhstan dated May 3, 2006 || - | ---------------------------------------------------------------------------------------------- |
Note. Items 10-22 of the Plan were excluded by Resolution No. 554 of the Government of the Republic of Kazakhstan dated June 15, 2006.
Action Plan
for the implementation of the Concept for the Development of the National Center
for Biotechnology of the Republic of Kazakhstan for 2006-2008
| Measures | Form of completion | Deadlines | Responsible executors | Estimated expenditures (million tenge) | Sources of financing |
|---|
Strategic Measures
1. Submission of proposals on the introduction of new academic disciplines at specialized higher education institutions for the training of specialists in technological management and biotechnology.
- Form of completion: Order of the Ministry of Education and Science
- Deadlines: October 2006
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Health, Ministry of Agriculture
- Estimated expenditures: No funding required
- Sources of financing:
2. Corporatization of the National Center for Biotechnology of the Republic of Kazakhstan through the establishment of a joint-stock company with 100% state participation.
- Form of completion: Resolution of the Government of the Republic of Kazakhstan
- Deadlines: June 2006
- Responsible executors: Ministry of Education and Science (coordinating body), Committee for State Property and Privatization, National Center for Biotechnology
- Estimated expenditures: No funding required
- Sources of financing:
3. Cooperation between the National Center for Biotechnology and foreign scientific societies and associations.
- Form of completion: Report to the Administrator of the Programme* (Ministry of Education and Science)
- Deadlines: March 2006 – December 2008
- Responsible executors: National Center for Biotechnology
- Estimated expenditures: 2.8
- Sources of financing: Private capital
4. Submission of proposals for the establishment of a state biological safety system.
- Form of completion: Proposal to the Government of the Republic of Kazakhstan
- Deadlines: October 2006
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Industry and Trade, Ministry of Energy and Mineral Resources, Ministry of Agriculture, Ministry of Health, Ministry of Environmental Protection, Ministry of Defence, National Security Committee (subject to agreement), National Center for Biotechnology
- Estimated expenditures: No funding required
- Sources of financing:
Investment Policy
5. Implementation of the investment project entitled “Development of the National Center for Biotechnology of the Republic of Kazakhstan”.
- Form of completion: Report to the Government of the Republic of Kazakhstan
- Deadlines: January 2006 – December 2008
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Economy and Budget Planning, Government of the Republic of Kazakhstan
- Estimated expenditures: 2006–2008 – 8495.34*, including by year:
- 2006 – 600.00
- 2007 – 4886.81*
- 2008 – 3008.53*
- Sources of financing: Republican Budget 011 “Construction and Reconstruction of Education and Science Facilities”
6. Construction of the “National Center for Biotechnology of the Republic of Kazakhstan”.
- Form of completion: Report to the Government of the Republic of Kazakhstan
- Deadlines: December 2006
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Economy and Budget Planning, National Center for Biotechnology
- Estimated expenditures: 2006 – 600.00
- Sources of financing: Republican Budget 011 “Construction and Reconstruction of Education and Science Facilities”
7. Further development of the infrastructure of the “National Center for Biotechnology of the Republic of Kazakhstan”, including:
1) introduction of the training of trainers methodology;
2) staffing, education and professional development.
- Form of completion: Report to the Government of the Republic of Kazakhstan
- Deadlines: December 2007
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Economy and Budget Planning, National Center for Biotechnology
- Estimated expenditures: 2007 – 4886.81*, including:
- 143.10*
- 103.32*
- Sources of financing: Republican Budget 011 “Construction and Reconstruction of Education and Science Facilities”
8. Completion of the construction of the “National Center for Biotechnology of the Republic of Kazakhstan”, including:
1) engagement of foreign scientists (Ph.D.) as heads of scientific groups of the “National Center for Biotechnology of the Republic of Kazakhstan”;
2) standardization of laboratories and premises in accordance with GMP, GLP and ISO standards;
3) introduction of the training of trainers methodology;
4) staffing, education and professional development.
- Form of completion: Report to the Government of the Republic of Kazakhstan
- Deadlines: December 2008
- Responsible executors: Ministry of Education and Science (coordinating body), Ministry of Economy and Budget Planning, National Center for Biotechnology
- Estimated expenditures: 2008 – 3008.53*, including:
- 207.53*
- 166.00*
- 143.10*
- 385.94*
- Sources of financing: Republican Budget 011 “Construction and Reconstruction of Education and Science Facilities”
Research and Development Work
9. Approval of the scientific and technical programme “Development of Modern Technologies for the Formation of a Biotechnology Cluster in the Republic of Kazakhstan for 2006–2008”.
- Form of completion: Resolution of the Government of the Republic of Kazakhstan
- Deadlines: April 2006
- Responsible executors: Ministry of Education and Science (coordinating body), National Center for Biotechnology
- Estimated expenditures: 2006–2008 – 1433.00, including by year:
- 2006 – 450.00
- 2007 – 477.00*
- 2008 – 506.00*
- Sources of financing: Republican Budget 002 “Fundamental and Applied Scientific Research”
\* The amounts of funding from the republican budget for 2007–2008 shall be subject to adjustment and submission for consideration by the Republican Budget Commission in accordance with the Law of the Republic of Kazakhstan “On the Republican Budget” for the relevant financial year.
\* Programme – Republican Scientific and Technical Programme “Development of Modern Technologies for the Formation of a Biotechnology Cluster in the Republic of Kazakhstan for 2006–2008”.
Note
List of abbreviations:
Ministry of Education and Science – Ministry of Education and Science of the Republic of Kazakhstan;
Ministry of Agriculture – Ministry of Agriculture of the Republic of Kazakhstan;
Ministry of Health – Ministry of Health of the Republic of Kazakhstan;
Ministry of Environmental Protection – Ministry of Environmental Protection of the Republic of Kazakhstan;
Ministry of Industry and Trade – Ministry of Industry and Trade of the Republic of Kazakhstan;
Ministry of Defence – Ministry of Defence of the Republic of Kazakhstan;
Ministry of Economy and Budget Planning – Ministry of Economy and Budget Planning of the Republic of Kazakhstan;
Ministry of Energy and Mineral Resources – Ministry of Energy and Mineral Resources of the Republic of Kazakhstan;
National Security Committee – National Security Committee of the Republic of Kazakhstan;
Committee for State Property and Privatization – Committee for State Property and Privatization of the Ministry of Finance of the Republic of Kazakhstan;
National Center for Biotechnology – National Center for Biotechnology of the Republic of Kazakhstan;
RB – Republican Budget.
Constitutional Law Code Regulatory Act Order Decision Resolution Lawyer Almaty Lawyer Legal services Legal Consultation Civil Criminal Administrative Cases and Disputes Defence Arbitration Legal Company of Kazakhstan Law Office Court Cases Declaration Decree Order Resolution Decision Report Conclusion Application Conclusion Convention Contract Memorandum Methodology Standards Note Rules Programme Charter Charter Article Commentary Resolution Regulations Protocol Draft Programme Rules Messages